Aziyo Biologics Inc - Ordinary Shares - Class A Stock

[Operator Instructions]

Please be advised that today's call is being recorded. I would now like to hand it over to our first speaker, [ Bernadette Eutroniak ]. Please go ahead.

Thank you, Operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the third quarter ended September 30, 2026. A copy of their press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995.

Any statements contained in this call that do not relate to matters of historical fact or relate to expectations of [ Federal Security Service ] are not subject to [ Federal Security ] predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For lists and descriptions of the risks and uncertainties associated with our business, please refer to the risk factors section of our public filings with the SEC, including Elutia's annual report on Form 10-K for the year ended December 31, 2025, and in our subsequent periodic reports on Form 10-Q and current reports on Form 8-K, accessible on the SEC's website at www.sec.gov. Such factors may be updated from time to time in Elutia's other filings with the SEC.

This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 5, 2026. Elutia disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise. Also during this presentation, we refer to gross margin, excluding intangible asset amortization, which is a non-GAAP financial measure.

A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available on the company's financial results release for the third quarter ended September 30, 2026, which is accessible on the SEC's website and posted on the Investors page of the Elutia website at www.elutia.com. And with that, I will turn the call over to Elutia's CEO, Randy Mills.

Thank you, Bernadette, and thank you all for joining us today. It is an exceptionally busy and exciting time for us at Elutia, and I'm eager to get you up to speed on our progress. Here's how we'll spend our time. First, the need. It is serious and the lack of attention being paid to it by industry is astonishing. Infection was a major focus at last month's meeting of the American Society of Plastic Surgeons in Houston. It came up in every one of the 11 breast research sessions, yet commercial products addressing it and no company on the exhibit floor was talking about a solution. That market dislocation has created a tremendous opportunity for Elutia.

Second, we'll review the great progress the team is making on NXT 41X. Our key GLP antimicrobial study met its predetermined endpoints. Surgeon feedback on the actual product was very favorable, and NXT 41X is set to head to the FDA this quarter. Then Matt will walk you through how we funded ourselves through launch without an equity offering. He'll also cover our cardiovascular business and its remarkable growth, take you through the third quarter results, and end with the milestones ahead. Then we'll open the line for your questions, including some that were actually brought in by you. Let me start with the need, because that is where everything at Elutia begins.

Infection in plastic and reconstructive surgery is common. It is serious and it remains unsolved. Over the next few slides, I'll show you what surgeons themselves presented on at this year's national meeting because their data and insights make the case better than we ever could. The ASPS meeting in Houston was last month, and to me, one of the most astonishing things that stood out above the rest was infection. There were 11 scientific sessions devoted to breast research. Infection risk and prevention were discussed in every one of them. Of the 135 research presentations, 70, or 52%, addressed infection.

Infection wasn't only covered in the research sessions, however. The conference included an entire course called 28 Years Later: Current Strategies in Salvaging the Infected Implant. Think about that. Surgeons have been fighting implant infection for decades, and it is still one of the biggest problems plastic and reconstructive surgeons face today. The data presented at the meeting were sobering. Investigators from UCSF reported on 1,094 breasts that underwent immediate implant-based surgery. In women who did not receive chemotherapy before surgery, 17.6% developed an infection. In women who did, it was 23%.

That is nearly 1 in 4. A second study from Miami Cancer Institute looked at 419 breasts. Every one of those patients received antibiotics before and after surgery, and 19.3% still developed an infection. These are leading centers following current best practices and infection still approaches 1 in 4, but in most cases, these are women who are already fighting cancer. Think about that. So why not just do what we normally do and give patients more antibiotics? Because it doesn't work. A 20-year multi-center study presented at the meeting answered that question definitively. It looked at 4,647 patients across 170 healthcare organizations. Extending antibiotics past 24 hours did not reduce infection at 30 days, 60 days, or 90 days.

And the biology explains why. Systemic antibiotics travel through the blood. A mastectomy closes off the very blood vessels that would carry those drugs to the surgical site. You can give more drug, but it can't get to where it needs to go. Which brings me back to what struck me most in Houston. In the session rooms, in the hallways, at the receptions, surgeons were focused on infection. 70 presentations across all 11 breast research sessions. I walked onto the exhibit floor and found a sea of commodity surgical matrices. There were literally 25 on the market and none are demonstrably different from the next. But no commercial offering for infection. No one was even talking about it. On one side you have surgeons and their patients living with this problem.

On the other, an industry that hasn't offered them a solution. That gap is the unmet need. It is the reason Elutia exists, and it is exactly what we intend to fix with NXT 41X. Now let me turn to how we intend to close that gap. NXT 41X is our lead drug delivery program. Our key GLP study is complete. Our manufacturing is set for commercial production, and we plan to submit NXT 41X to the FDA this quarter.

Let me walk you through where our programs stand. We currently have 2 product development programs, and both are on track. I want to be clear that they are on separate submissions on independent timelines. First, NXT 41, our biological surgical matrix without drug. The 510(k) is submitted, the review is progressing as expected, and we anticipate a clearance decision this quarter, and we have every reason to believe it will be favorable. However, it is largely academic at this point. NXT 41 has already done its job, which was to discover and answer FDA's questions about the base matrix.

We have no intention of commercializing NXT 41. It broke the regulatory ice for NXT 41X. And everything that we learned from it has been built into the NXT 41X platform. The more material submission is NXT 41X, our lead drug delivery program. Our key GLP study met its predetermined endpoints, and we plan to submit NXT 41X to the FDA this quarter. From there, we anticipate a clearance decision in the second quarter of 2027, a commercial soft launch in the second half of 2027, and a full commercial launch in 2028. That timing reflects our current expectations and is of course subject to FDA review.

All in all, it is a very busy but exciting time in R&D and regulatory. This is the study that supports our submission, and it is pretty cool. In a GLP rabbit implant study, NXT 41X met its pre-specified performance endpoints. We challenged it with MRSA, a drug-resistant gram-positive form of the most common pathogen in breast surgery, Staph aureus. We then challenged it with E. coli, a particularly nasty gram-negative rod that can cause serious infection and lead to sepsis. And we didn't make this easy. We put the bacteria on the uncoated side of the matrix, away from the drug, and we added a lot of them.

The MRSA challenge was 8 logs, that is 100 million bacteria. The E. coli challenge was 6 logs, 1 million bacteria. Both represent far more contamination than would normally be present in the operating room, creating true worst-case conditions. So, the results: after 7 days of implantation, we recovered 0 viable bacteria from the NXT 41X samples and surrounding tissue, 0. Contrast that with the matrix without antibiotics. Every animal implanted with the matrix alone developed fulminant colonization by those same pathogens versus 100%. Pretty cool. Data matter. But the surgeon's opinion matters too, since they are the ultimate decision makers.

While we were in Houston, our NXT 41X Surgeon Steering Committee met in person, and their feedback on the design, handling, and performance of NXT 41X was both informative and very positive. And while we talked about a number of different product attributes, 2 really stood out as the difference makers. And I wanted to share them with you since this is how a surgeon takes a look at a product like 41X. They put it simply, it's about the drug being in the right place at the right time. Right place to them means powerful antibiotics that are uniformly distributed across the entire surgical site. That's exactly where systemic antibiotics fail to reach. The right time means 30 days of coverage. Why? Because that carries them through drain removal, which usually happens somewhere around day 17.

It was simple, and it was a powerful message for us to hear, and it was gratifying for the team since that's what we designed NXT 41X to do. And we're ready to make it. Our automated drug coating system is set for commercial production. It gives us at least $300 million in revenue capacity at launch and is designed to support a gross margin above 80% at scale. That matters for 2 obvious reasons. First, we certainly don't want to be supply constrained as the product is launching. Second, we want to be able to make money with this product, and the margin profile we wanted was built into the manufacturing process from day 1.

So when you take a step back and you look at it, I hope you can see what we're creating here: a product for a true unmet medical need, one that already has been proven with our own technology that our own technology can answer, and one that we can make money with. And we have the capital and team and intellectual property to see it through. And with that, I'll turn it over to Matt to close out and then be back with you for Q&A.

Okay, thank you, Randy, and good afternoon, everyone. I'll start with our balance sheet because over the last 3 months we did just what we said we would do. We added $26 million without an equity offering. We believe that funds Elutia through the anticipated clearance of NXT 41X and the first year of commercial launch. On our August call, we named 3 near-term funding milestones, and I'm pleased to report that all 3 are now complete. First, on August 11, we closed a $15 million loan facility with Avenue Capital Group. We received $10 million at closing, and an additional $5 million becomes available following NXT 41X FDA clearance.

Second, on August 17, we closed the sale of our SimpliDerm business to Solution Biologics and received $8 million at that closing. We're also eligible to receive up to $3 million in contingent technology transfer payments over the next 18 months. Third, on October 1, Boston Scientific released the full $8 million holdback from the 2025 sale of our bioenvelope business with no claims and no deductions. Together, that's $26 million in just 51 days. That was a busy couple of months. We also have additional sources of capital that we expect will contribute to our runway. There's a $5 million second tranche from Avenue Capital and up to $3 million in SimpliDerm milestones as well as proceeds from a potential cardiovascular transaction should that happen.

As one of our remaining legacy businesses, I'd like now to focus a bit more on our cardiovascular business. Third quarter revenue there grew 20% year over year to $1.1 million. And for the first 9 months of 2026, revenue was up 65%. Third quarter adjusted gross margin was 85%. This business is performing well, but it is ultimately not where we're going as a company. As we've previously discussed, we've been pursuing a divestiture of this product line. We believe the sale makes sense for the company both as an additional source of non-dilutive capital and to provide strategic focus as we get closer to the launch of NXT 41X.

We've had significant interest in this asset from multiple parties, and the strategic process remains on track. Now, turning to a brief summary of our financial results. All the figures I'll go through are for continuing operations compared with the third quarter of 2025. Net sales were $1.1 million, up 20% from $0.9 million. Gross margin on a GAAP basis was 61.7% compared with 52.8%. The adjusted gross margin, which excludes non-cash amortization of intangibles, was 85.5% compared with 81.3%. Total operating expenses were $7.6 million compared with $6.4 million.

The increase was driven by $1.9 million of higher research and development spending on NXT 41 and NXT 41X, partially offset by a $0.7 million reduction in net litigation costs. In other words, our spending is shifting toward the programs that are creating value. Loss from operations was $6.9 million compared with $5.9 million. Net loss from continuing operations was $6.5 million compared with $1.0 million. The prior year figure benefited from a $5.1 million non-cash gain on the revaluation of warrant liabilities. Adjusted EBITDA was a loss of $5.6 million compared with a loss of $3.4 million. Reconciliations of our non-GAAP measures are included in today's earnings release.

We ended the quarter with $29.1 million in cash and cash equivalents, and that balance does not include the $8 million Boston Scientific holdback, which we received 1 day following the end of the quarter on October 1. To close, here's what our capital is funding. We had 3 funding catalysts that are now behind us: the Avenue loan, the SimpliDerm sale, and the $8 million Boston Scientific payment. 6 catalysts lie still ahead. This quarter, we expect an FDA clearance decision on NXT 41. We plan to submit NXT 41X to the FDA, and we have the potential to complete a cardiovascular transaction. In the first half of 2027, we anticipate an FDA clearance decision on NXT 41X.

A commercial soft launch follows in the second half of 2027, and our full commercial launch hits in 2028. And in closing, I'd like to mention a couple of investor events that are coming up. The first is a fireside chat with Dr. Al Hassanein, Associate Professor of Plastic Surgery at Indiana University. Dr. Hassanein is a pioneer in local antibiotic delivery for prevention of infection risk and breast reconstruction. He's also very knowledgeable about our development process for NXT 41X and its most salient features. This event is taking place on November 20 and is being hosted by Frank Takkinen of Lake Street Capital Markets. The event is open to Lake Street clients, but please contact Frank if you're interested in attending.

And the second event is the annual J.P. Morgan Healthcare Conference in San Francisco. We'll be hosting meetings there in our own space on January 11 and January 12. If you'll be there and you'd like to meet with us, please email [email protected]. And with that, operator, please open the line for questions.

[Operator Instructions]

First question from Frank Takkinen from Lake Street.

Hi Randy and Matt, can you hear me?

Hey, how's it going?

This is Sam Knapp on for Frank Takkinen. First, could you talk a little bit more about the barriers to entry and IP that you think will protect your competitive position? It would be interesting to hear where you think the strongest defenses exist, whether that be regulatory, product design, manufacturing know-how, or a combination of all of the above. Any color would be appreciated.

Yes, Sam. So, you know, when you sort of look at the question of, so why can't competitors come in and do this, there's 2 fundamental reasons that prevent that from happening. The first is we have built a very substantial intellectual property platform. Some of that we have chosen quite intentionally to keep as trade secrets. Some of that we have filed patent protection on and actually we continue to file and add patent protection to. And while the idea of a drug delivery matrix is nowadays beyond patentability itself, we think the features that we have designed into 41X, that we have intellectual property for [ Equidi matrix ] around, that we have patent protection around, are actually going to set what's going to be the only acceptable standard going forward and give us some really very meaningful protection in the marketplace. That's one.

Two is the reality of it. It's been 25 years. Infection's been known to every relevant player in this field for the past 25 years, and no one's done anything about it. And the reason they haven't done anything about it is because it's really, really hard to do. Our team here makes what we do look really easy. They are a group of flat out geniuses that have solved some very complex problems with some very sophisticated solutions. And sometimes perhaps I gloss over it a little bit too much, Sam, and almost make it sound too easy. It is not easy. This product platform has taken us 6 years to get to where we are today.

And so even if there were somebody that were going to decide to get involved in it, it is a long, hard road to figure out how to get powerful antibiotics to uniformly elute off of a biological matrix in a delivery form that surgeons will accept. And so we feel very, very confident that we have both an intellectual property and a regulatory barrier to entry that are going to keep us pretty much alone in this market for a while.

That makes sense, I appreciate it. And then one other one, once NXT 41X is submitted, how should we think about hiring expectations in advance of approval? I mean, how large of a commercial team will you hope to have in place at the time of the launch? And then maybe for Matt, in light of that, any initial thoughts on how we should think about OPEX going forward without SimpliDerm and the ramp-up investments in front of NXT 41X?

Yes, so I will, you know, I'll do the play-by-play here. Matt will do color commentary on the financial implications for it. But Sam, at the end of 2027, heading into the first full year of launch in 2028, we anticipate having the top 16 territories covered. The top 16 territories in the U.S. give us access to approximately 50% of the breast reconstruction market. We intend to do the vast majority of that through direct representation. We'll use 1099s to fill in some of the spaces in between, but we really want to own the major markets.

You may have seen, I know we have gotten questions about, and our HR department is flooded with applications, we have started the recruitment process for both sales leadership as well as direct sales representation in these markets. The plan is, by the way, not to bring them in too early, but to identify the best candidates in the markets that we need and go through the proper courting and vetting process to make sure that we're onboarding them when the time comes.

So that recruitment process has started, but we don't anticipate bringing on a real heavy recruitment share until really the second and the third quarters. We don't have any need to bring them on too early, since at least the third quarter of next year, if everything's on schedule, the third quarter of next year is going to be an exercise in VAC submissions. And, you know, sometimes VAC submissions are like watching paint dry, and there's no sense in having an elaborate and expensive commercial force sitting around with nothing to sell.

So 16 is where we're going with that, with the appropriate sales leadership, but we're not going to go crazy with it. We're not going to add too early. We think we're going to have great visibility into the 41X regulatory process as we begin to do that. So, if there is an unforeseen change in the timeline, we'll have the ability to adjust, but that's what's the plan for the year, Sam. Oh, you want to talk about money? Sure.

Sam, yes, I think a lot of what Randy talked about really are the indicators for what spend will look like. And those relate to the concentrated market that we're entering into, the fact that there's no change to the physician workflow, so the sales cycle should not be particularly long, and we're really going to be standing alone in terms of offering a product that there's a great need for in the market right now. So all of that we believe translates to what should be a pretty rapid ramp once we launch with high gross margins and a relatively small commercial organization needed in order to serve that market.

What that ultimately translates to, you know, we're going through our 2027 budgeting process right now, so it's a little bit too early to speak in specifics, but, you know, our goal really is to not have our burn rate change that much if we go through next year and actually start launching the product. So we'll see how that plays out. We'll have a little bit more specificity that we probably can offer on our next call. But we feel good about where we are and the cash that we have in the bank and the ability for that to fund us through the launch of NXT 41X.

Awesome, I appreciate that. And then just one more, on NXT 41X, what is left to be completed prior to the official submission? Is there any outstanding testing that could take a little longer, or are you pretty much just packaging the final submission packet?

Yes, the heavy lifting testing for NXT 41X is now complete. And what I mean by that are the pivotal performance studies, the studies that, you know, are the large animal studies that can go on for 6 months or longer. The product is up on stability testing now. This is when we do the final actual commercial-grade manufacturing of the product, take it through the entire cycle, and then test it over periods of time for shelf life. That will be an ongoing program. And so, you know, that will actually run, that will actually continue to run, we hope, long after approval of the product as we continue to extend the date. But the stability program is just an ongoing study that will continue to happen.

The rest of the data for the product is done or is being packaged. We have no more study. So, Sam, have you ever been sort of around some of these things? We're talking about all GLP studies that are done for every one of these things. Every one of them requires numerous types of sign-offs from the contract testing laboratories that do them in order to meet GLP processes. And so those types of things take a little bit of time. It is a massive submission, so it's, you know, something, it's thousands and thousands of pages. And so it is a big deal for our team to put together. I'll make it sound really easy, but nothing big outstanding at this point. Sam, that's why we're pretty excited about it.

Fantastic. Well, thank you for answering my questions, Randy and Matt, and congratulations on the progress so far.

Cool. Thank you. Thank you.

Thank you. And now I'd like to turn it back over to Randy for closing remarks.

Okay, thanks, and we actually are going to try something out here that I really like. We received a number of questions ahead of the call, too many to go through, but I thought I'd take a couple of them and answer them, and this is something we'll do on future calls. So on a future call, as long as you get your question to us ahead of time, we'll be glad to throw it into the queue.

Now a lot of questions we got, basically I'm going to pick a couple of questions here that were the most commonly asked questions, because there seems to be some confusion around those things. That lies with me, that's on me, so I need to do a better job communicating these. So let's start with the first one, which is please clarify the timelines for NXT 41X and how they relate to the NXT 41 regulatory process.

Well, first, I hope that what we had in the presentation helped a little bit there and described that they're both on independent timelines. I think that's the first really important point. NXT 41 and NXT 41X are on 2 separate development pathways. NXT 41X is not dependent on NXT 41. So we will file NXT 41X as soon as that regulatory file that Sam just mentioned is complete and it's ready to go.

Some sort of sub-questions I got: it seems like it's probably going to take like 9 months for NXT 41, and we're anticipating 6 months for NXT 41X. How do you reconcile those? Well, a couple of things. First is, just to clear up some things on the timing of NXT 41, NXT 41 was submitted by us in February, but it actually wasn't accepted into FDA until later in March, believe it or not. And that is when they started their review clock. So just so everyone knows, it isn't taking some unusually long time. The FDA just gave themselves a little bit of time to check our 510(k) submission into their process.

They're our friends. With regards to 510(k), I also think it's important to say that we're anticipating a second quarter submission. Why? Because we don't have any big studies to do. We're not waiting on any data. So we think the second quarter is the most likely time. We think they're going to ask us some questions in the first quarter. We think we'll be able to answer those questions in the second quarter and have our clearance in the second quarter of that year.

But you have to know that's an estimate. It could be earlier. It could be as short as 3 months, you know, and sometime come in April maybe. It could come in sometime in September. So it's our best guess at it, but there is certainly a range around it. We're dealing with a really complicated product and we're dealing with the Food and Drug Administration. So I wouldn't be setting your watch by the exact day, but it is our best guess at this point on what it would be. So thank you for that question of the people who submitted it. And I hope that clarified some of those points.

Okay, 1 more question, and that centers around the cardiovascular process. So where are we on the sale of the cardiovascular business? If it's not sold, what are the plans going forward? This is a great question. We have a great product with our cardiovascular product. In fact, it is the Cadillac of products that are out there for cardiovascular repair. It is a very sticky business. It is one that you've seen in our reporting. It's not just maintaining, but it's actually experiencing some very healthy growth since it returned back to the company from LeMaitre, and it has exceptional gross margins. So this is a product with 80%, 85% gross margins.

We make money with this product. So as you would expect, we have received interest in it, but here's what we're not going to do: we're not going to do a bad deal. If we have a serious acquirer that will complete a transaction that could have value for us, well, will have value for us, obviously, in terms of the cash that would bring in, but also value in terms of strategic focus, then we would do that, and we will do that, you know, as soon as we would be ready to do that deal, right? If that happens this quarter, then we're ready to go.

But we're not going to rush to get a bad deal done. There's a saying a friend of mine taught me: if you want a deal done badly, that's how you get it done. And we're not in a rush to do it because it's a great business and it's a growing business. And frankly, it's not that big of a headache and it's not a distraction for us. And so it is a milestone that we will meet, but only if we end up with the transaction that makes sense for us to do.

So, I hope that clarified it. I encourage you to ask questions, submit questions ahead of time. We'll have information about how to do that in the next press release. It's kind of fun. I like it and lets me know what you're thinking about and what you're worried about and, frankly, what I'm doing a bad job communicating on. But with that, I think we are done, and I will turn it back to the operator to close the call.

Thank you for your participation in today's conference. This does conclude the program. You may now disconnect. Everyone, have a great day.

This live transcript is auto-generated without human intervention or review.

Thank you. Good day and thank you for standing by. Welcome to the ILLUSIA Q2 2026 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again.

Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Bernadine Cherniak. Please go ahead.

Thank you, Operator, and thank you all for participating in today's call. Earlier today, Alusha released financial results for the second quarter and June 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the Federal Securities Laws which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation those relating to our operating trends and future financial performance, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For lists and descriptions of the risks and uncertainties associated with our business, please refer to the risk factors section of our public filings with the SEC, including Alusha's annual report on Form 10-K for the year ended December 31st, 2025, and in our subsequent periodic reports on Form 10-Q and 10-K, accessible on the SEC's website at www.sec.gov. Such factors may be updated from time to time in Alusha's other filings with the SEC. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 13, 2026. Allushia displays any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise. Also, during this presentation, we refer to gross margins, excluding intangible asset amortization, which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available on the company's financial results released for the second quarter and on June 30, 2026. which is accessible on the SEC's website and posted on the investors' page of the Alusha website at www.alusha.com.

And with that, I will turn the call over to Alusha's CEO, Randy Mills.

Thank you, Bernadine, and thank you, everyone, for joining us today. The second quarter was another solid quarter of execution for Alusha, so let's get right into it. Here's how we'll spend our time today. I'll start with why we are concentrating the company's efforts on the reconstruction opportunity. I'll walk through the highlights. of the quarter, including our strength and balance sheet and some exciting new survey data. Matt will take you through the financials and capital position, then we'll open the line up for questions. Four things defined this quarter. were funded up to 26 million of additional capital with no equity offering we believe that carries us through the NXT 41 X clearance decision in the first full year of commercial launch in 2028 and beyond Second, the company is becoming more focused as our strategic divestitures are being completed.

We signed a definitive agreement to sell Simpliderm for up to $11 million, and the cardiovascular process is progressing well. The purpose of this activity is to align the company's capital on the one thing that will drive the greatest value for patients and shareholders, the commercialization of NXT 41X. Third, we now have real data on surgeon demand for NXT 41X. In an independent, blinded survey of 50 Borg-certified plastic and reconstructive surgeons, 96% expressed interest in adopting NXT 41X. and 92% said that they would champion it at their hospital's value analysis committee. I'm going to spend some time on this study today because it's important. Thank you. And fourth, our regulatory and manufacturing teams continue to advance towards launch on schedule. This quarter, we had a productive meeting with FDA and the NXT 41 program remains on track for what we believe will be a favorable clearance decision in the fourth quarter.

Perhaps more importantly, we believe NXT 41X, the ultimate THE ULTIMATE GOAL IS WELL-POSITIONED FOR CLEARANCE IN THE FIRST HALF OF 2027. In preparation, our automated manufacturing process has been qualified for commercial production of NXT 41X at scale. For those newer to the Ilusia story, here are some of the is a short version of what we are uniquely great at. We combine a biological matrix with sustained local antibiotic delivery at the surgical sites. The objective is straightforward. Create a surgical implant that can prevent bacterial colonization before it has the chance to become an infection. And importantly, we have done this before. Our first generation drug eluting product, LU Pro, was the first FDA cleared antibiotic eluting bio envelope.

We developed it, we cleared it, we commercialized it, and last October we sold that business to Boston Scientific for $88 million. We are now applying that same technology to solving the very real problems that exist in plastic and reconstructive surgery. The United States market for breast cancer surgery is valued at $1.5 billion, and importantly, it is an established market. Surgeons already use biological matrices in breast procedures today. We do not have to create a new category. At the same time, the clinical problem is substantial. Published data show postoperative infection rates remain between 15% to 20% following mastectomy.

So the opportunity for us comes from the combination of three things, a large existing market, a significant unresolved clinical problem, and a technology platform that directly addresses it, a platform we created. And the magnitude of the problem is hard to ignore. These are published data, not ELUSHA estimates. Approximately one in three women experiences a serious complication following reconstruction. 15 to 20 percent experience postoperative infection. Up to 21% experience an implant loss. And the average hospital cost of a reconstruction with an infection is more than $48,000. That is a patient problem, a hospital problem, and it is a surgeon problem.

Now, we've shown you infection statistics before. What this slide shows are the consequences. Let's start with the patient. She's fighting cancer. That's why she's in the operating room. When an infection takes hold, chemotherapy stops, radiation stops, because she is looking at pain, fear, and more trips to the operating room. And if she loses the implant, more than half of the women in that situation never go back and finish the reconstruction process. It ends. The hospital incurs an added cost, mostly without reimbursement.

It gives up revenue generating operating room time slot and hospital beds, and it takes the reputational hit regarding its infection rate. But the surgeon pays a unique price, and they pay it over and over again. Keep this in mind because they are the ultimate decision makers regarding what gets used in the operating room. Let's look at a surgeon who does 140 cases a year and has the average infection rate of 17%. That means they are getting called back into the hospital every 15 days, irrespective of the time of day, day of the week, or whether it's a holiday, that significantly impacts their quality of life. If you don't think so think about this. The reconstructive specialty in plastic surgery is by itself an independent risk factor for burnout among plastic surgeons and when those surgeons walk away women lose access to reconstruction So now that you understand what we are doing and why, let me turn to how we funded the plan.

This quarter, we secured up to $26 million of additional capital without an equity offering. It comes from two places. First, a $15 million credit facility with Avenue Capital Group, $10 million of which is already in the bank. and another $5 million that is available to us upon NXT 41X clearance. That is not only a substantial infusion of cash, also an unequivocal endorsement of our plan by a sophisticated healthcare lender who conducted extensive due diligence. The second is the Simplet Earn transaction, which provides for up to $11 million in consideration. That includes $8 million in cash at closing and up to $3 million in tech transfer and commercial milestone payments. On top of that, at the start of the fourth quarter, we anticipate receiving the full $8 million in escrow from Boston Scientific. Now look at the bottom of the slide, because the timing is the point.

We believe this capital will take us through the NXT 41 clearance decision in the fourth quarter of this year. the anticipated NXT 41X clearance in the first half of 2027, and the full year launch in 2028 and beyond. We are now fully funded. The divestitures are a key part of the strategy. We made a deliberate decision to stop spreading capital and management attention across multiple businesses and concentrate Elluci where we believe we can create the greatest value. The SimpliDerm transaction is now signed with closing expected in the third quarter. previously announced strategic process for cardiovascular continues to advance with a potential transaction in the 2026 WHEN THAT WORK IS COMPLETE, ALUSHA WILL BE SOLELY FOCUSED ON ONE PRIMARY OPPORTUNITY, NXT 41X and the approximately $1.5 billion plastic and reconstructive surgery market. That was intentional and we are nearly done. Now to the part of the quarter I'm most excited about. For two years, we've been telling you the demand for NXT 41X is out there.

This quarter, we quantified it. We hired an independent market research firm to run a blinded survey. board-certified plastic and reconstructive surgeons states, averaging 11.6 years in practice and about 140 implant-based reconstructions a year. 42% practice in academic hospitals, and the group is split about evenly between east and west of the Mississippi. These are exactly the surgeons who will decide whether NXT 41X is ultimately adopted. A quick word about method. It was blinded. These are not our friends. We did not pick the respondents. Alusha was never named. Nobody was being nice to a sponsor because nobody knew who the sponsor was. Interest was measured using the standard with Wilson 95% confidence intervals. The first question was whether surgeons themselves see infection as a significant unresolved problem.

They estimated the surgical site infection rate at 17%. And that's right in the range of what the published literature says it is. The more striking result is on the right side. 86% of surgeons surveyed said the matrices they use today actually increase the risk of surgical site infection. And I want to be precise about that. That is not Alusha making a comparative claim about another company's product. It is the surgeons describing the product they currently use as an infection risk factor. Taken together, postoperative infection is a real problem that needs a better solution.

The next topic was whether the NXT 41X concept made sense to them. 96% rated the combination of rifampin and minocyclin effective at reducing surgical site infection. 64% said it was extremely effective, and not a single surgeon rated the antibiotic combination as ineffective. 98% view NXT 41X as new and different from products on the market today. The specific product characteristics they found most compelling were also telling. local antibiotic concentrations above the minimum inhibitory concentration for 30 days a bactericidal antibiotic combination directed against known surgical site pathogens. and prevention of bacterial colonization ranked one, two, and three, respectively. Those are not branding attributes. They are fundamental mechanisms of how our product works. And remember, there was no Aleutia brand attached to any of the survey. They were reacting to the actual product specifications. The third question is the one that matters commercially. Would you use it? For high-risk patients, including diabetic patients and those with high BMI, 100%, all 50 surgeons indicated they would use NXT41X.

Those two groups together represent approximately one-third of reconstruction patients, an enormous amount. opportunity in itself. But a full 96% said they were interested in incorporating NXT 41X into their general practice. And then there's the number on the right. 92% indicated a willingness to approach their hospital's value analysis committee in support of NXT 41X. I think that number deserves particular attention. Hospital adoption is not simply a matter of a surgeon liking a product or a product getting approved. Someone has to be willing to make the case internally and move the product through the hospital's VAC process. 46 out of 50 surgeons indicated they were willing to do that for this product. So let me put the whole study on one slide.

We asked if the problem was real. 86% said the matrix they use today increased risk infection. We asked if our approach would work. 96% rate the antibiotic combination is effective. We asked if they would use it. 96% expressed interest in incorporating it into their practice. We asked if they would fight for it. And 92% said they would champion it at their own hospital's vac. 50 surgeons, blinded and independent. Demand for NXT 41X is no longer theoretical. Turning to regulatory, I am very happy to say that for both programs, they remain on track and on schedule.

NXT 41, the underlying biologic surgical matrix without drug, is currently under FDA review. We recently had a productive meeting with the agency. And we continue to expect a favorable FDA clearance decision for NXT 41. the fourth quarter of 2026. That dialogue has also increased our confidence in our preparation of the NXT 41X submission. We expect FDA clearance for NXT 41X in the first half of 2027. Those remain the key regulatory milestones in front of us. Manufacturing readiness is advancing in parallel with the regulatory work.

This quarter we completed installation and operational qualification of the automated drug coding system. That system has already produced NXT-41X. For NXT 41X, we deliberately chose to own the manufacturing process ourselves. There is no contract manufacturer, license, or sole source supplier. The product is ours end to end. We also developed proprietary quality control assays and test methods to meet the FDA's very specific release criteria. The process is designed for scale, consistency, and efficiency, and we continue to target gross margins greater than 80% at scale. and it is now up and running at our GMP facility in Gaithersburg, Maryland.

All in all, a very solid quarter for the Ellucian crew, and I thank each and every one of them for their remarkable efforts. And with that, let me turn the call over to Matt.

Okay, thank you, Randy. Great to be here. I'll be hitting the highlights of our second quarter results and financial position. As a reminder, the impact of our bioenvelope business, which we divested in October 2025, shows up as discontinued operations in prior periods. However, the contribution of our simpliderm business in the second quarter still shows up in continuing operations, even though we entered into a definitive agreement to sell that business on July 11th. Assuming the closing of that transaction proceeds as expected, Simpliderm will also move to discontinued operations in future reports. Now, moving to our actual results. Total net sales for the second quarter were $2.4 million compared to $2.7 million in the prior year period.

There were two offsetting drivers. Simpliderm was down $0.7 million due to a production disruption at the product's contract manufacturer, but that was largely offset by an increase in cardiovascular, which was up $0.4 million on our transition back to direct sales. compared to $5.7 million in the comparable prior year period. Margins expanded meaningfully in Q2. Gap gross margin was 59.6% compared to 52.9% a year ago. Adjusted gross margin, which excludes non-cash amortization of intangibles, was 70.7 percent compared to 62.7 percent, an improvement of eight percentage points year over year. Total operating expenses were $9.4 million, down from $9.8 million. Within that number, we continued to shift spend towards the future. Net litigation costs came down $1.9 million, while research and development increased $1.5 million in support of the continued progress in NXT 41. and 41X. Loss from operations improved to $8 million even from $8.4 million a year ago.

Net loss was $7.6 million compared to $9.6 million in the prior year period, an improvement of $2 million that primarily reflects the absence of losses from the divested bioenvelope business. Net loss from continuing operations was $7.6 million compared to $7.1 million, and adjusted EBITDA was a loss of $4.6 million compared to a loss of $3.0 million a year ago. The change was driven primarily by the increase in R&D expense. Thank you. On the balance sheet, we ended the quarter with $19.9 million in cash. but we expect that position to be augmented by up to an additional $34 million from signed transactions. Going through those in a bit more detail, we received the initial $10 million this week from our deal with Avenue Capital. And in the fourth quarter, we expect to receive the full $8 million escrow from the last year's bioenvelope deal. The new Simpliderm deal adds up to $11 million, with $8 million of that $11 million coming at closing.

And next year, upon FDA clearance of NXT 41X, another $5 million becomes available under the Avenue Capital facility following the NXT 41X clearance. So, putting this all together, between our cash balance at the end of last quarter and the deals I just walked through. Total cash sources, both current and projected for the company, add up to $54 million. This This puts Alusha in its best financial position in a very long time. As Randy mentioned, this provides runway through at least 2028. And between now and then, this funding covers multiple expected catalysts. First, the closing of the Simpliderm sale this quarter.

Second, a potential cardiovascular transaction. Third, the $8 million escrow release. Fourth, the FDA clearance decisions for NXT 41 in the fourth quarter of this year and for 41X in the first half of 2027. In addition, the soft launch of NXT 41X in the second half of 2027. And finally, the full commercial launch of NXT 41X in 2028. So, stepping back, we believe the investment case for Alusha rests on three things. First, we have a validated platform. We have developed, cleared, and commercialized this technology once already in the form of Ellupro and sold that business.

Second, a blockbuster pipeline comprised of a $1.5 billion U.S. reconstruction market, an unmet medical need based on exceedingly high infection rates, and the now measured surge in demand behind our product. Third and finally, we now have a fully resourced company with a proven team, a built out GMP production facility, cash to fund the company through anticipated clearance and full commercial launch. The demand is real, the capital is secured, the regulatory path is on track, and the entire company is focused on success. And with that, operator, I'll turn it back to you.

and we can open the line for questions. As a reminder, to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. standby while we compile the Q&A roster. Our first question comes from Frank Takinen with Lake Street Capital Markets. Your line is open.

Great. Thank you for taking the questions and congratulations on all the progress. I wanted to start with one on FDA interactions. talk a little bit more about some of the conversations you've had, obviously, that you're comfortable sharing in a public setting, and then maybe detail what part of the process you're in with that clearance on 41. So with respect to 41, I...

I won't talk about too much of the inner workings of what we do, Frank. but I will say, um, that, uh, Michelle and her team, um, expected questions on 41. They received questions on 41. And they wanted to meet with FDA to discuss before submitting those responses to FDA to make sure that their answers to them would be what we hope are fully responsive. And so that was the nature and the reason of the meeting and we came out of that meeting feeling very good about where we are going forward with NXT 41.

Okay, very helpful. And then on the concept of manufacturing, appreciate the new color today. I'm curious if you could outline some capacity goals that you're thinking about as you prepare for launch. Maybe what level of capacity would you hope to have secured for the first full year of commercialization? And then what level of capacity might be required to achieve that 80% gross margin goal.

LATO? Yes, so we expect to have at least 300 million dollars of revenue capacity at launch of the product. Being able to expand it from there will not be a particularly significant challenge It will mostly involve additional personnel and additional shift adding, not additional space. not additional equipment or production lines.

So right out of the gate we expect to be able to meet.

a very a very sizable amount of demand and frankly we hope to be in a race uh keep up with it. With regards to gross margin, I The process for producing NXT 41X, Michelle and her team had the ability of designing 41X with the experience of LU Pro under their belts. they were able to look at the process and parts of the process and things that were inherent to the design of the product. that made that product more expensive and more challenging to make and drill up cost of goods of that product. And so when they designed 41X, they did that with that in mind and really have come up with a very elegant product process for manufacturing NX T41X. Some of that will depend ultimately on pricing decision when we talk about gross margins. One of the reasons, you know, we're just giving a rough estimate on range. But I think we would expect gross gross margins to be in an acceptable rate. you know, not too long into the commercial cycle. It wouldn't be something that, you know, we would be measuring in years before we got there.

Got it. Very helpful. Maybe on the commercial launch, maybe talk to what the limited launch might look like in the second half of 27, and then some of the most important items you'll be looking to check the box off, so to speak, before flipping to the full commercial launch.

to launch in 28. This is one of the great things, Frank, about getting older and having experience. This isn't our first rodeo. And so as we prepare to launch NXT 41X, we get to look back at the LU Pro launch, which was a drug eluding biologic going into a surgical procedure in modern times, today where we had to face value analysis committees. And value analysis committees, Frank, as you know, are the gating item on how fast the product has the potential to get adopted. And so, with regards to what we're thinking about soft launch activities, in the second half of 2027. It is Value Analysis Committee, Value Analysis Committee, Value Analysis Committee. We know that the more seeds that we plant early on with the VACs, the more... more revenue opportunity we will have as the year continues throughout 2028. With LU Pro, we developed a pretty sophisticated process for being able to go after those VACs.

And I would say Pete Ligotti and the work his team has done more recently with some more sophisticated targeting data, complication data, procedure volume data, will actually allow us to take, I think, what was some pretty sophisticated machinery and target it even further. further. What I mean by that is being able to go into a value analysis committee and literally show them their own hospital's data and their own hospital's problem. how much we would be able to help them, not just from a patient standpoint, from an economic standpoint as well. So that's what the soft launch for us is all about, is getting that done. We don't... We don't expect to be blowing the doors off of anything with regards to revenue because we still need to get through the front door of the vacuum before anything happens. So that's what we would expect to happen there. And then Frank, into 2028, I think come January 1st, if everything goes according to schedule, we'll be ready to cut it loose.

Very helpful. Maybe the last one, if I may, for Matt. Once the simpliderm divestiture is complete, how should we think about a OPEX run rate if you're excluding the litigation costs?.

Yes, you know, I think you could look at the various components of our operating expense, and certainly sales and marketing will come down significantly, really in proportion, I would say, to the revenue that we're taking out of the P&L. And it is not, potentially, not for the P&L. we could also be looking at something for the CV transaction. And that would be something that we could look at. That would actually put us for a short period into a situation where we would not be commercial. That would potentially allow for greater opportunities for streamlining and savings. Until then, we need to really maintain all the capability that we have. that we generally have now from an overhead perspective, but we're working hard on that and stay tuned. we're hoping to have something done there before too long. Got it. Very helpful. Thanks for taking the questions.

Appreciate it.

Okay. Thank you, Frank. Thank you. I'm showing no further questions at this time. This concludes the question and answer session and today's conference call. Thank you for participating. You may now disconnect.

This live transcript is auto-generated without human intervention or review.

[Call has ended.]

Thank you for standing by, and welcome to Elutia's First Quarter 2026 Earnings Conference Call. [Operator Instructions]

I would now like to hand the call over to Bernadine Cherniak. Please go ahead.

Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the first quarter ended March 31, 2026. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements.

For a list and descriptions of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including Elutia's annual report on Form 10-K for the year ended December 31, 2025. and our subsequent periodic reports on Form 10-Q and 10-K accessible on the SEC's website at www.sec.gov. Such factors may be updated from time to time in Elutia's other filings with the SEC.

This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 14, 2026. Elutia disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise.

Also during this presentation, we refer to gross margin, excluding intangible assets, amortization, which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available on the company's financial results released for the first quarter ended March 31, 2026. This is accessible on the SEC's website and posted on the Investors page of the Elutia website at www.elutia.com.

And with that, I will turn over the call to Elutia's CEO, Randy Mills.

Thank you, Bernadine, and thank you, everyone, for joining us today. The first quarter of 2026 was an important quarter for Elutia. We continued to sharpen our strategic focus. We advanced our NXT-41 regulatory program. We brought our automated manufacturing platform online, and we further strengthened our confidence in the commercial opportunity ahead of us in breast reconstruction.

Here's how we'll spend our time today. I'll walk you through the headlines of the quarter and where we're headed. Matt will take you through the financials and close with a few thoughts on what's ahead. Then we'll open the line up for questions.

Today, Elutia is increasingly becoming a pure-play drug-eluting biomatrix company focused on one of the largest and most underserved opportunities in reconstructive surgery. Four things I would like to highlight from the quarter. First, our FDA review of NXT-41 is progressing through productive interactions with the agency, and the dialogue has increased our confidence in the planned NXT-41x submission. We continue to anticipate NXT-41 clearance in the fourth quarter of 2026 and NXT-41x clearance in the first half of 2027.

Second, we brought our automated manufacturing platform online this quarter. That platform supports a target gross margin in excess of 80% at scale, enabling a differentiated value proposition at competitive pricing.

Third, direct surgeon engagement by our commercial team is confirming what we have believed all along, a $1.5 billion U.S. market, postoperative infection rates of 15% to 20% and no meaningful innovation in standard of care.

And fourth, we ended the quarter with a strong balance sheet, $36.5 million in cash and escrow, and we are actively engaged in 2 strategic processes, the SimpliDerm divestiture we previously announced and a newly disclosed inbound acquisition interest in our Cardiovascular product line. It is increasingly clear that within the $1.5 billion breast surgery market, NXT-41x has the potential to be a blockbuster and to meaningfully improve outcomes for women with breast cancer.

For anyone new to the Elutia story, here is the short version of what we do. Our approach is simple but differentiated. We combine a proven biologic matrix platform with sustained local antibiotic delivery designed to prevent bacterial colonization and the cascade of complications like infection that can follow.

Importantly, we have done this before. Our first-generation drug-eluting product, EluPro, was the first FDA-cleared antibiotic-eluting bioenvelope. We developed it, we cleared it, we commercialized it. And last October, we sold that business to Boston Scientific for $88 million. That prior success gives us confidence not only in the technology itself, but also in our ability to develop, make and commercialize differentiated drug-eluting products. NXT-41x takes that same validated platform into a much larger market with a much larger unmet medical need.

We believe the opportunity in front of us is transformational for 3 reasons: One, it's a big market, a $1.5 billion in the U.S. alone. Two, it's a big problem. 15% to 20% of patients develop postoperative infection after mastectomy. And if anything, that number is conservative. And three, we already have a proven solution. The $88 million that Boston Scientific paid for our first-generation product tells you that it works.

Let me put the market into concrete numbers. Approximately 168,000 breast reconstruction procedures last year were performed in the United States. Biologic mesh is utilized in more than 85% of those implant-based reconstructions. Biologics account for roughly 65% of the total procedural spend and human biologic mesh today sells for somewhere between $7,500 and $9,500 per breast. Put that all together, and you have $1.5 billion U.S. market opportunity.

This is not a market we have to create. It already exists. Biologic matrices are already deeply embedded into the standard of care. Surgeons use them in the vast majority of these procedures. Our job is simpler than building a new category. We just have to give them a better version of what they're already using.

In breast reconstruction, the unmet need for this is severe. One in 3 women suffer a serious complication after reconstruction. 15% to 20% develop a postoperative infection, up to 21% experience implant loss and the average hospital cost of a single infection ends up being more than $48,000. But remember why this woman is in the operating room in the first place. She was diagnosed with cancer. Her #1 goal is to beat that cancer. And when infection takes hold, chemotherapy stops, radiation stops, everything stops until the infection is resolved. This is not a minor complication. This is a cancer treatment derailing event and the standard of care today does not solve it.

NXT-41x is not a passive support mechanism. It is an active partner in recovery. It is easy to use. It fits the surgical workflow the surgeon already knows. It's cost neutral to the hospital. It replaces legacy products that they're already buying and it delivers powerful, sustained uniform antibiotic coverage right at the surgical site where systemic antibiotics struggle to reach. Unlike legacy biologic matrix with -- that have little functional differentiation, our goal is to deliver differentiated functionality at a competitive economic profile. We believe that matters.

With that backdrop, let me walk you through the work we did this quarter to advance the program. Let me first start with the FDA review. We continue to have productive interactions with the FDA regarding the NXT-41 submission. As a reminder, NXT-41 is the base biologic matrix, and it serves as the foundation for NXT-41x drug-eluting version that will follow.

While we're not going to comment on every detail of the review process, what I can say is that our dialogue with FDA has increased our confidence in the planned NXT-41x submission strategy. The discussions have helped clarify what FDA views as important from a submission standpoint. We continue to anticipate NXT-41 clearance in the first quarter of 2026 and expect NXT-41x clearance in the first half of 2027. The point I want you to take from this slide is our confidence has increased.

Let me shift to manufacturing. One of the most important accomplishments this quarter was bringing our automated manufacturing platform online. We have now installed and operationalized the core automated production equipment intended to support NXT-41x manufacturing at scale. This is strategically important for several reasons: First, the robotic coating system enables precise and reproducible application of the drug-eluting layer onto the biologic matrix. Second, the integrated in-house approach is designed to support scalability, efficiency and quality control. And third, we believe this process creates a meaningful competitive advantage.

The integrated process supports a targeted gross margin of above 80% at scale and an 80% plus gross margin gives us real pricing room against incumbent products that sell for between $7,500 to over $9,500 per breast while still delivering best-in-class margins. Said differently, NXT-41x is designed to compete both on outcomes and cost. That is a hard combination for an incumbent to respond to.

Now let me turn to commercialization, which I'm particularly excited about. Our commercial readiness work continues to increase our confidence in the market opportunity. Since joining Elutia, our Chief Commercial Officer, Pete Ligotti, has spent a substantial amount of time in the field speaking directly with surgeons and hospital stakeholders and the feedback has been remarkably consistent.

The clinical need is real and it is significant. Surgeons describe postoperative infection in downstream complications as one of the most frustrating challenges they face in breast reconstruction. Second, there remains a clear lack of meaningful innovation anywhere within this category. And third, the commercial opportunity appears to be highly concentrated.

Look at this funnel. As we discussed, the U.S. breast reconstruction market is $1.5 billion, and there are about 168,000 procedures performed last year. About 1,800 U.S. hospitals perform reconstruction, but only 585 of those hospitals account for 3/4 of the entire market and the top 50 centers alone represent over $300 million in spend.

Here's the insight. This is a $1 billion-plus U.S. market, but the real volume is concentrated at a few hundred hospitals, this is not a market that requires thousands of accounts or a massive sales infrastructure to establish meaningful penetration. We believe targeted engagement with high-volume centers can create substantial leverage, and that is exactly the team Pete is putting together.

Before Matt walks you through the financials, let me briefly address our strategic process. As we have previously discussed, we continue to evaluate opportunities to further focus the company around NXT-41x in its platform. With SimpliDerm, interest is strong and the process is going well. SimpliDerm is a high-quality business, $2.1 million in revenue in this quarter at a 57% gross margin. We have strong reimbursement coverage with approximately 100 million covered lives across UnitedHealthcare, Anthem and 9 regional plans, and it has a differentiated patent-protected manufacturing process.

But separately, we have received inbound acquisition interest in our related Cardiovascular product line. For context, that business did $1 million in revenue this quarter at an 85% gross margin, and that's up from $300,000 just a year ago. These are strong products with differentiated clinical profiles and attractive gross margins.

However, as we evaluate the company strategically, our priority is ensuring that capital, resources and management attention are aligned with the largest long-term opportunity for value accretion, which is NXT-41x. So we are going to provide further updates on both processes as appropriate.

Now with that, I'd like to turn the call over to Matt.

Okay. Thanks, Randy. I'll begin with a review of our first quarter financial results from continuing operations, which exclude the divested BioEnvelope business that we sold to Boston Scientific in October of last year.

Total net sales for the first quarter were $3.1 million compared to $3.0 million in the prior year period, growth of approximately 6% year-over-year. SimpliDerm revenue was $2.1 million compared to $2.6 million a year ago. Cardiovascular revenue was $1.0 million compared to $300,000 in the prior year period. The increase in Cardiovascular was primarily driven by a return to direct distribution, but also to improved procedural volume.

Turning to profitability. GAAP gross margin for the quarter was 58% compared to 47% in the prior year period. Adjusted gross margin, which excludes amortization of acquired intangible assets, was 67% compared to 56%. The year-over-year improvement reflects favorable product mix and price improvements.

Total operating expenses were $8.2 million, essentially flat year-over-year. Inside that number, we reallocated meaningfully. Litigation costs declined by approximately $2 million as we work through legacy matters, and we redeployed that capacity to achieve the substantial R&D progress and commercial readiness for NXT-41x.

Net loss for the quarter was $7.5 million compared to a net loss of $3.9 million in the prior year period. Adjusted EBITDA was a loss of $4.4 million compared to a loss of $2.8 million a year ago. Importantly, the increase in net loss was driven primarily by noncash items and other expense, specifically the revaluation of warrant liabilities and not by any deterioration in the underlying operating business.

From a liquidity perspective, we ended the quarter with $28.5 million in cash on hand, plus the $8 million escrow associated with the BioEnvelope divestiture, which we expect to be released in the fourth quarter of this year. Combined, that represents approximately $36.5 million in cash and escrowed receivables. We believe our current capital position provides the resources necessary to support our planned regulatory and operational milestones.

For shares outstanding at quarter end, the company had approximately 44.2 million common shares outstanding and 3.2 million prefunded warrants, representing 47.4 million common equivalents outstanding.

Now let's look ahead at the catalyst calendar. We continue to actively work towards our strategic transactions, the SimpliDerm and Cardiovascular processes that Randy discussed. Each of these would further bolster the balance sheet. We continue to anticipate NXT-41x FDA clearance in the fourth quarter of 2026. And in the first half of 2027, we anticipate FDA clearance of NXT-41x. In the second half of 2027, we anticipate commercialization and a focused NXT-41x soft launch.

Overall, we believe the first quarter reflects continued execution against our strategic priorities. We are maintaining financial discipline while investing in the core capabilities required to support the NXT-41x opportunity.

Now taking a step back, we believe Elutia today represents a unique combination of attributes. We have an established drug-eluting biomatrix platform. We have prior experience successfully commercializing and monetizing products developed on this technology, most notably the sale of EluPro to Boston Scientific for $88 million. We have existing GMP manufacturing infrastructure that is now online. We have growing regulatory clarity from our productive dialogue with FDA, and we are pursuing a large market opportunity, $1.5 billion in the U.S. with a meaningful and well-documented unmet medical need.

All the pieces are coming together. And most importantly, we have a company capable of creating meaningful value for surgeons, for hospitals, for shareholders and most importantly, for patients. We have the platform, we have the market, we have the team, and we have the resources to make it happen.

Operator, we're now ready to open the line for questions.

[Operator Instructions] First question comes from the line of Frank Takkinen of Lake Street Capital Markets.

Congrats on all the progress. I was hoping to start with one on the follow-up. I know you said you wouldn't divulge too much detail on it, but I'd be remiss if I didn't ask. So maybe how I will ask is, if I heard you correctly, you said incrementally more confident. So maybe the way for us to understand it is no surprises with perhaps a more detailed roadmap for 41x. Is that a fair way to think about it? And any other detail you would provide?

Yes. The way I would describe it is, one, any time that you submit something to FDA, you submit to a particular group. And so while it's the same regulatory pathway that we use with EluPro, we went from cardiovascular with EluPro over to plastic and reconstructive surgery. And what we found with the review team in plastic reconstructive surgery, which is unique than the one in cardiovascular is a group that is significantly more collaborative and engaging and very proactive in the review process.

And so given how sort of early on we are in the review, we've had a tremendous amount of dialogue back and forth, substantive communication, direct communication with the agency on this, not just the perfunctory type of letters and initial things that might go back and forth to the state, but real serious meaningful conversations in a productive and collaborative fashion. And that's obviously been helpful in 41 and 41 is moving along the way we anticipated 41 would move along.

But sort of keep in mind, as we do, I would hope, Frank, that our eye is actually on the prize and the price is 41x. And what we're really doing with 41 is making sure that our 41x submission is the highest quality submission we can have it, that it's on time and most importantly, that 41x gets approved when we anticipate. And the interactions we've had so far in the 41 process has given us a lot of confidence in where we're going with 41x. I hope that adds sort of the color and commentary around what's going on.

No, that's perfect. I appreciate that very much. Maybe on the -- some of the new commercial comments, thanks for that color. It was very educational. I was hoping to ask about maybe a question that's a little bit too far out right now to be thinking about, but I'm sure you're starting to sketch it up. How do you think about rep hiring? Obviously, a very concentrated call point. I think in the past, you've used a hybrid of kind of internal as well as 1099s. Maybe talking about that split and when you start to maybe bring on some of that early talent.

Right. So it's certainly a little too early to lay out the full plan. We'll be doing that more now that Pete's on, but I do have a couple of comments on it. So the first, one of the things Pete is doing is Pete is doing a really nice job of going out and assessing the market both qualitatively and quantitatively, Frank. And I mean when you bring a sophisticated guy in-house, right, this is what they do.

Quantitatively, it's great to know, hey, what's the actual infection rate? Where are all the procedures done? How -- what are the kinds of infections and complications are they seeing at different hospitals and centers and things like that.

The qualitative side of it is what do the surgeons think is going on? I mean the -- anyone to spend any time with the surgeon is their perception of the problem can oftentimes be very different than the actual problem. And the gap between those 2 is actually where the real marketing plan and genius and opportunity come about and take shape.

So what we're seeing and what Pete's already uncovered is when you start looking for -- when you start looking at the high concentration in centers, so I think it was 585 accounts for 75% of the market. And then even that ends up being super concentrated, we have $300 million of market opportunity in just 50 accounts. But I mean, let's put that into perspective with what we did with EluPro. We took 12 direct reps with EluPro, pair them up with a handful of 1099s and in 9 months, they activated 193 VAC accounts, right, for submission in 193 accounts. That would be like, I don't know, $0.5 billion of market opportunity in breast reconstruction, right? It's absolutely incredible what's going on here.

And then just to go on, I get really excited about this, as you could tell, Frank. But another thing that Pete uncovered is if you look at the postoperative complications that are happening, we mentioned in the press release that he's confirmed the sort of the market size and this concentration effect that we're seeing, but also the severity, it's really interesting because when you look at the complication rates of these high-volume centers, they are really high. You're looking easily at 30% complication rates at these high-volume centers.

And so it's kind of nice that the earliest places to go to get some big wins are actually also the ones that need the most help. And intuitively, if you sort of think about it, that's not too surprising because these are the big centers where people are getting referred with the more complicated cases that are -- that have the comorbidities that lead to infection that require the more radical mastectomies and all of those factors that lead to postoperative infection. But it's really, really gratifying to see it come together.

So we will have more -- just to go back to your actual question, Frank, we will have more on the launch structure coming up. I think probably by the next conference call, we'll be laying that out a little more clearly with a little more sophistication. But boy, in 60 days, the man has hit the ground running and has confirmed what we know and then has taken it really to the next level with this, and it's super exciting, particularly when you put it in the context of what we were able to accomplish with Little old EluPro. And now you talk about game-changing 41x, and we can't wait.

Very helpful. Maybe just my last one. How do you think about maybe time lines around SimpliDerm and Cardiovascular understanding. It's always challenging to predict, but any wise goalposts you provide?

Well, we started the SimpliDerm process. We announced that on our last call. Interest was very robust. I think we had something like 38 targets engaged in it. I would say we have confidence -- we have pretty good confidence that a transaction is coming together. Frank, I just -- it's like trying to pick the final 4 or enrollment in the clinical trial, like trying to time when a deal like a divestiture is going to happen, just leads to bad promises and expectations. I will say we are very pleased with how the SimpliDerm process is going. We're looking for a high-quality deal, and we think we're on track to get one. But until it's done, it's not done.

And then on the Cardiovascular side, the air was pretty much just a lot of surprise from the upside because we got actually a number of inbound requests on the Cardiovascular side, and there's high-quality interest in that product as well. And as we think about strategic positioning of the company, you could probably tell, right, we are really, really convinced in the 41x opportunity that lies ahead, not just the capital that this would add to our balance sheet and strengthen our balance sheet even further than where it is, but also the strategic focus and the alignment and the management attention and all of those other things.

These are 2 great product lines that are used surgically every day and patients benefit from them every day. But they're just not where we're going as a company. And it will -- I think both of these will have a meaningful impact to our balance sheet and to our strategic focus. So did that help?

Yes. Very helpful.

Thank you. Ladies and gentlemen, that does end our Q&A session and concludes today's conference call. Thank you for participating. You may now disconnect.

Good day, everyone, and welcome to Elutia Fourth Quarter 2025 Financial Results Call. [Operator Instructions]. Please note, this conference is being recorded. Now it's my pleasure to turn the call over to Sonali Fonseca. Please proceed.

Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance are based upon our current estimates and various assumptions. These statements include material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For list and descriptions of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including Elutia's annual report on Form 10-K for the year ended December 31, 2024, and in our subsequent periodic reports on Form 10-Q and 10-K, accessible on the SEC website at www.sec.gov. Such factors may be updated from time to time in Elutia's other filings with the SEC.

This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 11, 2026. Elutia disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements because of new information, future events or otherwise. Also, during this presentation, we refer to gross margin excluding intangible asset amortization, which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available in the company's financial results released on the fourth quarter and full year ended December 31, 2025, which is accessible on the SEC's website and posted on the Investors page of the Elutia's website at www.elutia.com.

And with that, I will turn the call over to Elutia's CEO, Dr. Randy Mills.

Thank you, Sonali. Good evening, and welcome to our fourth quarter 2025 earnings call. We are coming to you live from our Gaithersburg, Maryland facility, and I'm super excited to be here, wherever you are, however, you may be listening welcome. We are super glad to have you. I'm going to try to keep my comments brief tonight. But on that point, you guys know, I may fail. We have so many exciting things going on in Elutia right now, and I am eager to share them with you. So with that let's just jump in. Here's a forward-looking statement slide that basically says what Sonali just said, and then really quickly on our conference call.

So what's on the agenda today, we're going to go over some of the basics. You guys may have heard this, but we also have a lot of new callers on the call today. So be patient as we go over things like our mission and what we're good at. Where we're headed as a company, we made a couple of announcements in that press release that are kind of important. And so we'll be updating we'll be updating some of those things there. Matt is going to then talk about finance topics. And then lastly, we will close the call and take your questions.

So let's start off with our mission. Humanizing medicine, so patients can thrive without compromise, humanizing medicine. Humanizing medicine. Every 98 seconds a woman in this country is diagnosed with an invasive form of breast cancer. That means even if I keep my remarks short today, there will be 18 new cases diagnosed during this call. Three of those are going to die during this call. 10 will have breast reconstruction, and 3 are going to have a serious complication from that surgery. Who are these people? These are our mothers, these are our wives, these are our friends and our daughters. You know them. That is humanizing medicine. I'm looking around this room right now at a group of brilliant overworked, tired professionals and the look on every one of their faces is the same. Randy? Let's go get at this.

So why do we think we can fix this appalling problem, Well, let's look at what we're good at, what we're great at, actually. We are great at combining an optimal biological matrix and we use the biological matrix to hold an implant in place and regenerate into the patient's own healthy tissue. That's an essential part of the surgery. But what we do that no one else does is we combine that with powerful antibiotics for sustained antibiotic release that prevents infection in these other complications that we're talking about. Infection is the #1 complication of surgery period, and we have the ability to significantly reduce it. And this isn't theoretical, right? We've already done this.

EluPro we launched in January of last year. We got it through 194 [indiscernible] in 9 months. We guided up to an $18 million run rate because physicians loved it, and most importantly, it works. And so that's what we're doing with 41x into breast reconstruction. We can't do this without an incredible team, and I am super pleased to announce that we have done a great job adding some serious horsepower to our team this last quarter. I'd like to welcome Guido Neels as our new Board member. He is an operating -- he is an operating partner at S6 Woodlands and the former Chief Operating Officer of [indiscernible] Corporation, he's also importantly, a long-time friend and mentor of mine, and we are blessed to have him join the team.

I'd also like to welcome Pete Ligotti as our new Chief Commercial Officer, Pete joins us with a brilliant 30-year career, including 20 years at Integra, more time at NuVasive, where he ran a successful business. He's going to be coming in here, and he's going to be spearheading our commercial efforts as we move towards the launch and commercialization of 41x. Welcome to both of these gentlemen to the Elutia crew.

Okay. So where are we headed? Where are we going? I want to be really clear about all this, so everybody understands. We are going to solve a really big problem that exists right found in breast reconstruction. And why this is such a transformational opportunity for us really comes at the intersection of three things. One is a really big market. It's a really big market, and that matters. Breast reconstruction is a $1.5 billion market. But it's also a really big market that's facing an enormous problem. As I said, 15% to 20% of our breast reconstruction patients will develop a serious postoperative infections, just unacceptable. We can do better. We have to do better. And the good news is that our technology platform is almost purpose-built for this specific problem.

Our first FDA cleared drug-eluting bio envelope turns out to be a really, really great way of addressing breast reconstruction infection. And so that's what we're going to do. So digging in here a little bit, breast reconstruction is a really big market. There are 162,000 breast reconstructed after mastectomy annually, that means there are a lot of biological matches that are already being used, biological matches already used in 90% of the surgery. So what does that mean? It means we don't have to train a surgeon on some brand-new technology to solve their problem. We just take a technology that they're used to, that they're familiar with using and make it much better so it solves their #1 problem. Human ADMs, human acellular dermal products lead this market, and they're expensive. We're going about $7,500 to $9,500 a breast, that makes them 65% or more of the total implant spend during a breast reconstruction procedure. So this is a really, really big market.

But it's a market that confronts some very unique challenges. When I talk about the postoperative infection rate being 15% to 20% people look at me and think, "Oh, that just couldn't be. That just couldn't be. It is, it definitively is. And I want to explain just a little bit about why? Why we see such high infection. I'm not going to go through all the slides I as some of you may have seen this, I have a longer series on this. But I do want to show you what's really at the root of this. So when a mastectomy, all of the breast tissue has to get removed. If all of the breast tissue isn't removed, woman's mastectomy isn't complete, and they have to go through follow-up and surveillance and mammograms and other types of things and still have a risk for redeveloping breast cancer. So all of this tissue has to be removed.

Well, one of the things that you should sort of know about breast tissue is that the blood supply for the anterior or the front side of the breast, it all goes through this breast tissue that has to get cut out. And so -- when a mastectomy is done and that tissue is removed, the blood vessels, and therefore, the blood supply for the front half of the breast is removed with it. And that closes off that blood supply. And what does that do? Well, that creates a situation where you have an area of the body that your blood flow can't reach where your immune system can't readily reach. And very importantly, where postoperative antibiotics can't reach. You can give somebody oral antibiotics or you can give somebody intravenous antibiotics, but if they don't have a vasculature to a particular area those antibiotics aren't going to flow there. And this is what sets up the very unique problem that we see in breast reconstruction. And that's what leads to these exceedingly high infection rates.

As I said, 1 in 3 women suffer a serious complication, about a 15% to 20% experience an infection. This isn't one paper. This isn't some esoteric citing. This is the registry. This is what all of the data says, in fact, put it into real specific numbers, the registry data says it's 12% to 37%, if you want to put the real numbers about it. So when we say 15% to 20%, we are not exaggerating on that number, if anything, we are being conservative. And this is validated every time we go out and talk particularly with the academic centers where they really, really, really track these numbers very, very closely. That leads to up to a 1 in 5 implant loss. So they've got to go back and this whole thing comes out. It leads to a massive economic burden for the hospital, $48,000 economic burden to the hospital. So the hospital certainly should be highly motivated to address this problem.

But I just want to keep in mind and go through our mission here in humanized medicine. We're also talking about a woman that started this journey because she was diagnosed with cancer. Not an augmentation. She was diagnosed with cancer. And the #1 goal in that woman's mind is curing herself from that cancer, and that involves chemotherapy, it involved surgery. It involves radiation sometimes. And when an infection pops up, all of that stops. None of that can go on until that infection is resolved. And so this is a significant problem on so many different fronts. And it's one that if you can't tell, we are very, very passionate and committed to solving.

So the great thing about this anatomical problem that's set up during the mastectomy is kind of creates a perfect environment for what we do. So what if we flip the script on this infection? And instead of trying to deliver this antibiotic systemically, we delivered it locally. We actually delivered it where the breast implant and the drain are, through the mesh, which is naturally there anyway to hold the implant in place. Well, the exact opposite would happen. Instead of concentrations being very, very low of antibiotic, the concentrations would be very high, and they would stay high, for a long period of time. And then the best part, they wouldn't have any systemic effects. So you can have high therapeutic concentrations of antibiotics right there in the breast side, without any of the systemic side effects that you sometimes get when you deliver systemic antibiotics. And this was the concept that we started out with a very long time ago. This was the premise behind EluPro, and when we started using EluPro in humans, we saw it was completely valid. And then we got more data on this specifically in breast reconstruction. So there's some really great data out there on what happens if you deliver antibiotics locally, into the breast reconstruction space. There two different studies, particularly that I'll reference here.

One of them uses a plaster antibiotic plate. Now, that doesn't sound like a great way to treat a woman who's undergoing breast reconstruction to put a piece of plaster in her breast. But when the risk of post-operating infection is 15% to 20%, desperate times call for some pretty desperate measures. So they gave it the shot. They impregnated this plaster with this antibiotic, and they looked at it in just the general breast reconstruction population. What they saw is a 62% reduction in infection risk. We're talking about going from 12.6% to 4.8%. This was not a small study. We're talking about 593 patients in here. So a significant proof of concept that if you deliver these antibiotics locally, you can do a really, really good job of preventing infection.

Another version of this was tried but in a much, much higher risk setting, here, what they were looking at is instead of using these big plates, they use these little plaster beads. Again, they're just plaster material. And they put those into the breast cavity. But what they were looking at here were women who had very, very poor, in fact, pathologically poor blood flow to the anterior side of the breast I'm going to call, mastectomy skin necrosis. And this is where there's just literally no blood supply to the front part of the breast and that front tissue starts to die. When that happens, it's your risk of infection skyrockets. And so here, they saw an 82% reduction in infection. We're talking about going from 36% down to 6%, again, end of 75% here. You might say, well, again, maybe this problem is solved, not really, even the authors and these are friends and champions of Elutia who are behind these studies will tell you this is a suboptimal solution to a very serious problem. No one wants that plaster put in there. Nobody -- no plastic surgeon wants to make [indiscernible] beads off-label in the back part of their surgical center. They don't stay in place. They drop down into the inferior side into the gutters of the breast. They don't provide uniform coverage and they elute the antibiotic way too quickly.

But it did show that this concept definitively works. And that's why we created NXT-41x. We're combining these powerful antibiotics by [indiscernible]. So these are antibiotics that specifically target the pathogens we know we see in breast infection. And it delivers them in a uniform field for an extended period of time, by 30 days, a lot less this 30 days about. The drains that are placed at the time of surgery stay in for 17 days. And so you want a couple of weeks of extra coverage. That's what that's about. And we combine these powerful sustained antibiotics with an optimal biologic matrix. And that matrix, I'll refer to as 41. It's just the matrix by itself. And we put those two things together when we made something purpose-built for the problem that we're trying to solve, which is postoperative infection in breast cancer surgery.

So let's talk about the road map and how do we get from here to there. Right now, we have a simpler, we're going to talk about that in just a second, but that's our current product that's used in the breast construction space. It gives us a lot of practical on the floor experience in this space. But the real excitement starts with 41 and 41x. So 41 is our base matrix. So when I say NXT-41, I'm talking about just the biological matrix alone, without antibiotic, it is a phenomenal matrix in its own right. If we weren't a drug-eluting biologics company, we would be talking about this incredible NXT-41, but we can't leave good enough alone, primarily because it doesn't solve the biggest problem in breast reconstruction. But what we do is we use 41 from a regulatory standpoint to set the foundation for 41x. We announced today that we have already submitted to FDA, NXT-41. Let me just sort of pause [indiscernible] of this year that we will get clearance for NXT-41, and that will serve as the platform for NXT-41x, which is the base matrix combined with the [indiscernible], and if we put the time lines together, we expect clearance for NXT-41x towards the end of the first half of 2026. So we're looking at a second half launch of that product.

Okay. What's going on. A lot of people ask what are you guys doing inside the company. Well, you can sort of divide it up into three major work streams. The first one is obviously development. No surprise here. That group is focused pretty heavily on the approval of a highly differentiated product that significantly improves outcomes in plastic and reconstructive surgery. That starts with our 41 base matrix and rolls seamlessly into our 41x drug-eluting matrix. I said we're here in our beautiful Gaithersburg facility. Well, that allows me to introduce manufacturing this is our manufacturing facility here where we have enough capacity to make 41x for the foreseeable future. I think we have something like $120 million in revenue generating capacity from 41x with just one ship right now. So we have this great manufacturing facility.

And basically, I could sum up manufacturing jobs right now into two things: One, ensuring adequate supply of perfect quality tissue; and two, driving down cost of goods. So that's what they're working on. And then lastly, we now have Pete [ Legotti ] coming in and heading commercial, building these KOL partnerships, going to tell you, we do not have a problem getting a meeting and building strong relationships with our KOLs. We have and are continuing to build a very robust KOL team of champions, and there's really no secret to it. We're being able to do it not because we have great personalities, but because we're addressing their #1 problem and the #1 problem that their patients are facing, right now.

In addition to that, Pete's working on developing health economic models, obviously, spending a lot of time on reimbursement strategies and generally preparing for launch readiness of 41x. So now let's turn a little bit to SimpliDerm. We're exploring SimpliDerm strategic options. We announced that on the press release today. You might ask, well, why now?

Well, we've gotten to the point where our confidence with the 41x program really dictates that this is now the time for us to focus all of our time, all of our resources, all of our energy on making sure we do a great job with that platform. SimpliDerm is a great product. And whoever gets this asset is going to get a really, really wonderful product, acellular dermal matrix that's used in soft tissue reconstruction. It's got great handling. It's sterile, it's hydrated and ready to use, which is what the plastic surgeons want. Hundred million lives covered. This is a big deal. Some people think they could introduce their own acellular dermal product really quick and just get it on the market. It turns out reimbursement in the acellular dermal matrix market is a really big deal. So we have 100 million lives covered across -- from 2 of the largest payers. Anthem and UnitedHealthcare as well as 9 regional plans. It's patent protected, obviously. It's completely stand-alone. So for us, it's a completely securable business that doesn't cause any disruption. And whoever gets it, it's EBITDA accretive. So no incremental capital investment is required, its really a beautiful plug-and-play technology. So we'll keep you updated on this, and we'll see how that process goes.

Lastly, I wouldn't be able to say any of the great things that I'm saying today, and we wouldn't have been able to make any of the progress that we're making without our incredible Elutia crew. We are proud to be recognized for something we already knew. Elutia is a great place to work. And we were certified by The Great Place to Work certification. The results I thought when I saw them, I was really proud. It proved we are a mission-driven organization. We are also a merit-driven organization. 54% women, 62% of our leadership roles are occupied by women. 50% have advanced degrees. We are a brilliant group, not me, but the team. An entire 1/3 of our organization has a doctorate, and we are a committed group. Our average tenure 6.3 years. The advantage, if you're wondering what's the advantage of this great place to work certification. Well, the certification is kind of nice. I guess you can stick it on the wall.

But what it means is that compared to our noncertified peer competitors. We tend to outperform on financial metrics by fourfold. We are able to attract job seekers because of The Great Place to Work certification with a 15x higher attractiveness. And our or turnover of certified workforces is about half that of the regular U.S. workplace. So I'm going to end my comments there by thanking this tremendous team for frankly making my job such a joy. And with that, I will stop talking and I will turn it over to Matt Ferguson.

Okay. Thank you, Randy. And before I start my remarks, I'd just like to say I so appreciate the passion and the leadership that you've brought to the organization, and I support all of the comments that you just made about our mission and our market opportunity and probably most importantly, our team. And with that, we put out our earnings press release today with quite a bit of detail on it, and we'll put out our 10-K in a couple of days. I [indiscernible] even more detail on it. So I'm just going to hit a few highlights and not take very long here. But moving into a summary of our fourth quarter financial results.

From a revenue perspective, we did $3.3 million in revenue, and that compares to $2.8 million in the year ago quarter. That's up 16%. So we were very pleased with that performance. That was really driven by the return to direct distribution for both our Cardiovascular and our SimpliDerm product lines, as we've talked about. The return to direct distribution has also had a very positive effect on our gross margins. So on an adjusted basis, which is probably the more -- the better indication of how things are really performing from a business perspective, we had a gross margin for the fourth quarter of 66.8%. That was up 12 points from the prior year quarter when it was 56.5%. So really nice results there.

Our net loss from continuing operations, so that's excluding the BioEnvelope business that was divested on October 1. That net loss from continuing operations was $6.5 million versus $7.2 million a year ago. And then probably a more relevant metric in terms of our operating performance, our adjusted EBITDA which is a non-GAAP metric, but excludes certain noncash nonrecurring, noncore operational metrics. That was a loss of $4.2 million in the quarter compared to $3.4 million in the year ago quarter.

On our balance sheet, a lot has changed in the last quarter. As you know, our total cash on hand plus the $8 million that we have in escrow is $44.4 million. So puts us in a really nice position from an overall cash point of view. That is after having paid off all of our debt with SWK, that took place at the beginning of the fourth quarter as well. That was about $28 million that went to pay off that debt. And then just from a share count point of view, we have 42.8 million common shares outstanding as of the end of the year. In addition to that, there are 4.5 million prefunded warrants that are outstanding, so a total of 47.3 million. And all of those common shares outstanding now are Class A common shares. So what that means is that all of our Class B common shares, which were held by one entity were converted during the quarter and sold them to the market. So that is essentially an overhang that is gone now, and we're very pleased to get that behind us.

One of the effects that we've seen is that has gotten behind us is that we recently came back into compliance with all of NASDAQ continued listing requirements. We put out that press release at the beginning of last week, and I'd just like to thank all of our investors out there who put their trust and their capital into Elutia, and help support that return to compliance there. So moving on just to take a step back and at a big picture level, the fourth quarter of 2025 and really all of 2025 represented a real strategic reset for the company. And the biggest event in that really was the $88 million sale of our BioEnvelope business to Boston Scientific, which, again, that allowed us to pay off all of our outstanding senior debt to SWK left us with $44.4 million of cash on the balance sheet and in escrow that will come in later this year. And it really allows us to be completely focused and extremely well resourced for the continued development and the launch of NXT-41x, which we truly believe will be transformational in the market starting next year.

So I guess with that, the last thing I'd like to mention is just that we've tried to be very active in getting the story out, which we truly believe in. We've been active in getting it out to investors, and we're going to continue to do that. We have two conferences coming up in the next couple of months. The first will be just next week, the Sidoti Small Cap Conference, which is an online congress. And then in May, we have the LD Micro Conference, which is a live conference in Los Angeles. So if any of you are attending those events, we'd very much love to meet with you there.

So with that, in summary, before turning it over to questions, I'd just like to reiterate that the three key points of our story, we have a validated technology platform that's been proven by the sale of our EluPro product and our BioEnvelope business last quarter, to Boston Scientific, $88 million. We have a truly blockbuster pipeline underway, which is really starting with NXT-41x and a $1.5 billion market. And then we are in a great position from a resource point of view. We have a fantastic team. We have a great facility that we're sitting in here today. and we have a strong balance sheet, which will take us through that approval and into commercialization. So with that, open it up to questions, and back to you, Carmen, to start that off.

[Operator Instructions] We have a question from the line of Frank Takkinen with Lake Street Capital Markets.

Congrats on the progress. Congrats on the 41 submission to the FDA. I was hoping to start with a few questions around that. I know it's a question along the lines of trying to predict the unpredictable. But as you're working importantly, what kind of questions are you preparing for from the FDA? And kind of how do you think about the challenges you might have to go through to get it to market or if it should be a relatively streamlined process? And then secondly, once you do get 41 across the goal line, how quickly can you shift the filing to 41x and resubmit?

Okay. Just writing making some notes, Frank. So Frank, thanks for the questions. I think everyone should I think everyone should view the review process and respect the review process, I would say, the way we do. The time lines that we've laid out for clearance, have -- they're fairly conservative. And they're fairly conservative because we want to make sure that we do a really professional job. Now I think, first and foremost, we submit a high-quality application with everything in it that we think is necessary for a clearance. We do retain a lot of back up data on -- and supporting data on all the necessary points. But as a matter of sort of regulatory strategy and sort of best practices in regulatory science, you don't over-answer a question with FDA. You just be prepared to sort of explain the rationale for the things that you did answer. And so that's really the strategy that we have going on.

The -- there's no question that biocompatibility for some -- a product like this is a big question in the mind and a big focus right now in the Food and Drug Administration, we know that. we feel pretty good about our product there. We know that when we get into 41x, if we just remember back to the days from from EluPro, that things like in vitro elution was a real big point with them. You probably remember the IVF. Frank or IVE days, and so we're prepared for any and all of it, but we're prepared for it in a a very humble and respectful way. And that's the time lines we've set up, have that in place. And I would just sort of encourage everyone to just kind of keep that in mind. I wouldn't be pulling forward any time lines until we tell you that's probably a good idea.

With regards to how fast we roll into 41x. I would say just to kind of keep in mind the whole purpose of 41 is to improve the efficiency of 41x. We have no intention of commercializing 41. It's not a drug-eluting matrix. And so it doesn't fit with our high-level thesis. So really, the only reason that we're doing it is for regulatory efficiency. And therefore, the team will learn from the 41 submission they'll call any audibles that they need to as a result of what we learned from the 41 submission. But clearly, their plan is to go pretty efficiently from 41x -- or from 41 into 41x.

And if at any point, we think that, that might not -- that 41 might no longer serve that purpose, well, then we might change the plan. We might even pull forward a 41x submission. But right now, we anticipate in the time lines we anticipate we anticipate an approval pretty efficiently after 41.

Got it. Very helpful color. I was hoping to ask a little bit more about commercial. I appreciate some of the comments you made there, but kind of related to SimpliDerm. I think we've talked about just having experience in that space be a SimpliDerm could help kind of the commercial readiness of the organization once 41x is approved. How do you kind of think about balancing that readiness that SimpliDerm could have helped with versus the strategic process. And then at the same time, what are you may be doing from a commercial perspective in light of kind of that transition that is occurring?

Right. So Frank, let's kind of go through this with the three things that really help us get ready for 41x. One is just the base understanding of this market how it works and that includes the reimbursement, right? So we've done that. We do understand how this current market work how reimbursement works here, who the players are, literally, the logistics of a breast reconstruction products. So we think we check that. You will remember, by far, the most important thing in the commercialization of EluPro, was the Value Analysis Committees, like the VACs. And I'll be completely honest here, we learned more about how to do that efficiently with EluPro than probably we learned or are learning from SimpliDerm. 194 VACs in the time that we did that. I mean that was so key to the explosive growth of that product. And we have a team that understands that. We know what to do from a VAC package standpoint. So we feel pretty good about that.

The third piece, though, was KOLs and key opinion leaders, and who are the thought leaders in this space. And here's Frank, where our thought process has really flipped and it really started flipping when we when we were able to go last October to the big plastics and breast reconstruction meeting in New Orleans. And just cold call some of these marquee leaders in the field of plastic and reconstructive surgery and said, "Hey, would you mind having a conversation with us, we're trying to develop a locally delivering biological matrix for breast reconstruction. Deliver antibiotics to try to prevent infection.

Our dance card fill, and it filled with some of the brightest strongest thought leaders in this space, and that continues to this day. We have no problem getting meetings with these KOLs and engaging in very meaningful, very enthusiastic conversations with them on how we can best design, build and deliver a product that is exactly what we need. And so when that last piece sort of started to happen was when we sort of made the decision. We're we're probably pretty good here and can start moving on, particularly with the progress the R&D team is making with the filings.

That's perfectly clear. I got it. One last one I wanted to ask, Randy. Obviously, the data is really impressive with the plate as well as the powder with 60% and 80%-plus reductions. How do you think, and it's a speculative question, but how do you think NXT-41x could compare from an infection reduction perspective in relation to some of these other tech things that are being used today?

We would be thrilled with the 50% reduction. Anyone would be thrilled with something like that. We have some advantages, though, over those techniques that are delivering those results. Those advantages are uniform distribution. So as I said, with the plates and the beads, those things they have [indiscernible] to them, and they notoriously sort of fall down into the breast gutters, and don't provide uniform coverage. The second thing is the teams that were doing that work. They know that antibiotic comes out of that real fast. And therefore, it doesn't provide a particularly long-term coverage.

We targeted this 30 days, and we targeted the 30 days because the drains come out, at day 17. And if the drains are still in particularly with -- there's a piston-ing that can happen with each [indiscernible] from the outside of the inside, you're constantly introducing and have the potential to introduce bacteria back into that surgical field. So we felt pretty strongly that you needed to have antibiotic coverage after that persisted after the drains were filled. So we feel like we've probably built a better solution than the ones -- than what you're seeing these really, really fantastic results. So you can't knock what they're seeing.

But I think I want to caution everyone here again, too, a little bit of humility and perspective. There is a percentage of these cases that have such severe necrosis. This is where the vasculature to the breast is so compromised that it doesn't matter what you would put in there. The tissue just dies. And in that case, those -- we can add antibiotics all day long, but we're not going to prevent what's ultimately going to become something more like a gangrenous infection and the complications for those. And that's really just an unsolvable at least at this time, consequence of the base mastectomy. So does that help?

Thank you so much. And ladies and gentlemen, this concludes our Q&A session and our conference for today. Thank you for participating. You may now disconnect.

Good day, everyone, and welcome to Elutia Third Quarter 2025 Financial Results Call. [Operator Instructions] Please note, this conference is being recorded.

Now it's my pleasure to turn the call over to Matt Steinberg, with FIN Partners. Please proceed.

Thank you, operator, and thank you all for participating in today's call. Earlier today, Elutia released financial results for the quarter ended September 30, 2025. A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that do not relate to matters of historical facts or relate to expectations or predictions of future events, results or performance, are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and descriptions of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our public filings with the SEC, including Elutia's annual report on Form 10-K for the year ended December 31, 2024, accessible on the SEC's website at www.sec.gov. Such factors may be updated from time to time in Elutia's other filings with the SEC. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 6, 2025. Elutia disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements whether because of new information, future events or otherwise.

Also during this presentation, we refer to gross margin, excluding intangible asset amortization, which is a non-GAAP financial measure. A reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure is available on the company's financial results release for the third quarter ended September 30, 2025, which is accessible on the SEC's website and posted on the Investor page of the Elutia website at www.elutia.com.

With that, I will turn the call over to Elutia's CEO, Randy Mills.

Thank you very much, Matt, and welcome one and all to our third quarter 2025 conference call. I'm excited to be here with you today. Matt Ferguson, our Chief Financial Officer, is also with us today on this call. We're going to be going over a couple of things. One is the basics of evolution, a couple of things that I think everyone should know about the company. We're going to talk -- I'm going to spend a lot of time talking about where we're headed and not just where we're headed, but why we're going where we're going. Matt is going to give us an update on finance and litigation status. And then lastly, we'll close and take your questions. So let's get into it with some of the basics.

So Elutia, we are a mission-based company. I think that's an important thing for investors to know. And I think that's a good thing, too, because we have a great mission. Our mission at Elutia is humanizing medicine so that patients can thrive without compromise. And today, we're going to talk a lot about breast reconstruction. And I hope that you can appreciate that our work in this space is so necessary because there's a patient population right now, women experiencing and making their way through their breast cancer journey who really are faced with a lot of compromise in their care and in their treatment, and that's holding them back from thriving. And we are applying our talents, our resources, our efforts and our mission to overcome that. So these women are able to thrive without compromise.

I think it's really important for a company to know what they're good at, what are their strengths. And at Elutia, we are really great at combining biological matrices with powerful antibiotics that create this sustained antibiotic release in implants that's able to prevent infectious complications from happening. We started in this with EluPro, our first antibiotic eluting product that we got on the market and really did a great job in the initial commercialization with. We sold that, as you guys know, to Boston Scientific for $88 million. And now we're taking that technology into NXT-41x, which is our next-generation matrix for breast reconstruction. So if you're new to the story, and I see there are a lot of new callers on the call today, three sort of things that are probably worth keeping in mind. One is this is a validated technology platform. What do I mean by that? Well, we've already done it. We've already developed the first FDA-approved drug-eluting bioenvelope for pacemakers, which we sold to Boston Scientific. Now there, we're talking about a much smaller market, so only a $600 million market with a much smaller unmet medical need. We're talking about infection rates on the order of about 3%. We're taking that same technology platform, and we're moving it into a much bigger market with this blockbuster 41x that we have coming. So it's the same technology platform, but applied to the $1.5 billion breast reconstruction market. And as you're going to see coming up, there, we're talking about an unmet medical need where women are facing postoperative infection rates between 15% to 20%. And then lastly, the company is now fully resourced. We have the right team in place. We have a state-of-the-art GMP manufacturing facility, and we have a commercial platform already in place with our SimpliDerm product that we already have and we're already distributing in this space. And then very importantly, we now have the cash to fund the company, not only through product development and product approval, but all the way through commercialization of this technology as well. So let's get into it and let's talk about where we're headed and more importantly, why we're headed there.

So why breast reconstruction? Why is breast reconstruction such a transformational opportunity for Elutia? Well, it's really the convergence of 3 factors that make this a very special opportunity for us. One, as I've mentioned, breast reconstruction is a large market, $1.5 billion market. But two, it's an unusual opportunity in that it's this large market that still has this really significant unmet medical need, postoperative infectious complications of 15% to 20%. Despite our best efforts in this for the last 30 or 40 years, we just haven't been able to crack this. And then lastly, our technology, our proven technology platform works in this space, and we're going to be able to solve this significant problem for these patients by applying our technology to this area. So let's go through these three different parts, right? Let's start with the large market. And I get out and I talk to a lot of different investors about this. I think this is actually one of the pieces of our story that most investors already appreciate.

The breast reconstruction market is a really big market. It's an addressable market of about $1.5 billion. Why? There's 162,000 breast reconstructions performed in the United States annually. These are brand-new 2024 numbers from ASPS that are out. Biological meshes are already used in 90% of these reconstruction cases. So there's not like there's a market here that has to be retrained on how to use a biological mesh. And in fact, not only are biological mesh is the dominant modality -- treatment modality in these cases, they're also incredibly expensive. So we're talking about per breast on the order of $9,000 a breast for the biological matrix alone. And if you look at that as the percentage of implant spend, right? So you take the permanent breast implant, you take the expander that has to go in there and you take the biological matrix, you put all that together, the biological mesh is 65% of the implant spend. Here's the problem. The outcomes are abysmal. Despite the high cost, the status quo here isn't addressing the problem. Now I want to be really clear. I'm not suggesting the biological matrices causing the problem. I'm not suggesting the implants are causing the problem. I'm certainly not suggesting that the surgeons are causing this problem, but they're not fixing the problem. And what we're left with here is 1 in 3 women that go through breast reconstruction suffer a serious complication after that reconstruction fully, 15% to 20% of that is driven by infectious complications. We're talking about serious postoperative infections coming out of this case. And we are probably understating this problem in this case. Ultimately, we're looking at up to 21% of the implants end up being lost. The procedure ends up being a failure and has to be abandoned. That, as you can imagine, leads to this very significant economic burden that the hospital faces. We're looking at $48,000, the average economic cost to the hospital of an infected breast reconstruction. So here's a real significant problem. So like I said, when I go out and I tell the story, I think people appreciate that the breast reconstruction market is large. I think they even appreciate that -- hey, I believe you guys are going to get this approved. You did a pretty good job with that with EluPro. You got that there. You seem like you know what you're doing. They struggle to believe that this problem could be this bad in this big of a market for so long, and they really want to know sort of why -- how could that be? Why is that? And so I want to explain to you why this is the case. So here we go.

So there are some very unique challenges that are presented by mastectomy. So in mastectomy, all of the breast tissue has to be removed, and this is done by the oncologic breast surgeon that comes in and it does the removal of the breast tissue. Why is this happening? This tissue has to come out because if any of it remains, then there is still a risk for breast cancer redeveloping in that woman. And then there needs to be further monitoring. There needs to be mammograms, right? So the whole purpose of having a mastectomy sort of goes out the window. And so the breast surgeon comes in here, and they're very aggressive with this removal, right? So they need to take out all of this breast tissue all the way to the margins of the skin, all the way down to the chest wall. The problem with that is, as you can see in this diagram here, is that the vasculature for the breast runs through this very tissue that all has to come out.

Again, the vasculature of the breast runs through the tissue that has to come out. And so what happens is when you remove this tissue from the breast, you have to tie off these vessels that get cut, right? And so when you tie off these vessels, then you basically create an area of hypoperfusion, right, where you don't have adequate amounts of blood flow. What's the consequence of that? Well, the consequence of that is, generally speaking, the way we deal with and the way we prevent postoperative infection is by antibiotic therapy. We can give the patient oral antibiotics or we can give the patient IV antibiotics. But the idea is that you give these patients antibiotics and they circulate all through the body. and go to the parts of the body that you're looking to protect and prevent infection. But when you remove the blood supply, you also remove the route in which systemic antibiotic therapy needs to reach the surgical pocket. So no blood supply means no antibiotic therapy can reach where it needs. And there's lots of studies that show this.

The plastic surgeons refer to postoperative antibiotic therapy often as voodoo. It makes everyone feel good that they're taking these antibiotics, but it does not prevent postoperative infection. And the reason why it doesn't prevent it is this very real anatomical challenge that's created. It also, by the way, if antibiotics can't get there because there's no blood, it also makes it for a real challenge for even the patient's own immune system to get there. And our natural cellular components of our immune system have a far more difficult time. So after we've done this procedure, we've done the mastectomy, now a plastic surgeon, this is a different surgeon now, a different surgeon and a different surgical team comes into the operating room to do the reconstruction of this area where they have this really thin skin. You have this pocket of tissue that doesn't have any vasculature. And now in there, they need to put an implant of some sort, either the permanent implant or oftentimes an expander. And then the other thing they'll also put in there is they'll put in surgical drains. And these are drains, if you've never seen them, these are literally plastic tubes that port directly to the outside and they allow excess fluid that normally would accumulate there to drain out of these spaces. And so you're adding this large foreign body and you're adding these drains that communicate with the outside and create a portal for contamination to enter.

Then lastly, there's a mesh, right? And this mesh then goes around this entire construct to hold the implant in place and to create a bit of a barrier between the skin and the implant. And the reason that's done is because the skin here that's left after this radical mastectomy is so thin that you need something. And so that's what -- that's what meshes are used for in these types of procedures. And this is all done in a surgical procedure that's taking somewhere on the order of 4 to 6 to 8 hours in order to do. So if you wanted to create the perfect recipe for postoperative infection, it would be difficult to come up with a better recipe than the one we have here in breast reconstruction. You have long surgical times, 4 to 6 hours, multiple different surgical teams, creating an ischemic area in the body, right, that is hypoperfuse, doesn't have as much blood flow as it would need. On top of that, you put a large foreign body and then just for good measure, you throw a drain in that ports directly to the outside.

So the question isn't how do we end up with postoperative infection rates of 15% to 20%. The question is, how is it not 100%? I mean it's almost miraculous that you could do this procedure and not have more infectious complication. And I think that actually is really a testament to the surgeons and the professionalism of the surgeons and the operating teams in this case because this is just almost the perfect storm for an infectious complication. But we think about this differently. We look at this and we say, what if we flip the script here? What if we turned things over? And instead of having those antibiotics delivered systemically and hoping some trickle into this avascular necrotic space, what if instead we delivered them locally. So what would happen in that case? Well, in that case, you would have local concentrations of antibiotic that were much higher, that were at therapeutic or even super therapeutic levels. And then just to boot, you would have systemic levels of antibiotic that were essentially indetectable.

So you would have antibiotic exactly where you needed it, being very effective at preventing infection and you would completely avoid side effects that can come along with prolonged antibiotic and antimicrobial use. And so this is the fundamental basis behind what we do at Elutia, this idea of drug-eluting biologics and local antibiotic delivery. And this is what we did with EluPro, and it worked very successfully there. And it's what we're doing here with 41x. And the good news is we're not alone here. It's not like we thought of this and like, hey, aren't we brilliant and I wonder and I hope this works. Really resourceful inventive, creative plastic surgeons out there who are doing the best they can for their surgeons have already been looking into this. And they've actually already demonstrated proof of concept. And what they've discovered is that local antibiotic delivery in breast reconstruction works. It effectively, it statistically significantly reduces postoperative infection.

Now the problem with it is they had to borrow techniques from orthopedic surgeons in order to pull this off. And there's just 2 different examples here. This first one on the left, these are PMMA plates, polymethyl methacrylate plates. Said differently, they are a place of cement, like a bone cement, hard, big rigid disks. And basically, what they do with these plates is they're able to mix this stuff up in the operating room. And while they're mixing it up, they'll mix in a powdered antibiotic into the aggregate and make that as part of this bone cement. And they will literally put this bony plate up into the breadth. Now the problem is not permanent, it's not absorbable. -- it deforms the rib cage. It's -- but you know what it does really effectively. It prevents postoperative infection. So decreased infection, this is a study with 360 patients, right? This decreased infection of about 62% from 12.6% to 4.8% p-value less than 0.01, really beautiful statistical data that shows that if you have local delivery of these antibiotics, that they will effectively address this postoperative computation. Another version of the same thing is instead of making a big disc, what happens if you made little ease out of it and sort of sprinkle them in there. And again, the same thing.

Now this was a case -- or this was a study that was -- if you're wondering why the infection rates are so high. This is actually looking at salvage cases where the patients were already being brought back to the operating room for tissue necrosis. Now normally, what would happen is that procedure, the implant procedure would just be considered a failure. Here, they wanted to see if they could salvage these cases. And so they tried with and without this local antibiotic delivery. And again, a 35% postoperative infection rate dropped to 6.3% postoperative infection rate. This is a 75-patient study, p-value 0.017. So highly statistically significant. The point of all of this is if you deliver local antibiotics, it doesn't just conceptually work, it works in practice. And so that is why we created NXT-41x. But we did it in a way that the plastic surgeons are excited about using. And so Dr. Williams and her team has made a beautiful biological matrix. It's one of the things we're really good at doing that's purpose-built for plastic and reconstructive surgery. And then on to that, they've added powerful antibiotics, rifampin and minocycline. And they've done this in a way where they formulated it so they have a greater than 30-day release of these antibiotics that's putting therapeutic levels of antibiotics into the space for greater than 30 days.

Why is this 30-day number so important? Because most drains come out by day 17. And so you want to make sure that once the portal is closed to the outside, that you still have antibiotic delivery going on and they're able to address infections. So this is NXT-41x. And that's the rationale why we came up with this. That's why it was so important for us to get EluPro done and commercialized and then ultimately, in the hands of Boston Scientific, who are going to knock the cover off the ball with that product. So we can move on and bring this product to market to the women who are going through breast cancer, who are battling breast cancer and so desperately need this technology.

Let's talk a little bit about the plan and how we're going to get there. Right now, we have SimpliDerm, which is our biological matrix that doesn't have any antibiotics. This is very analogous to those of you who remember, our CanGaroo product that we had on the market, before we introduced EluPro, just the biological matrix by itself. So that's our SimpliDerm product. And what it enables us to do, just like CanGaroo enabled us to do is build out our commercial infrastructure, our sales team, our contracting team, the teams that work with the value analysis or the VAC committee, build out that whole infrastructure, so it's up and functioning and ready to go when NXT-41 comes to market, right? Second step, and you'll see this in the second half of next year, you'll see the first step is approval of NXT-41. Now what we're doing here, NXT-41 is NXT without the antibiotics. So if you think about the X is Rx prescription, right? So the NXT-41 is just the base matrix. We're doing that for regulatory purposes. We want to get just the matrix cleared through the FDA before we add the combination of the drug to be able to separate a combination device drug review into its component parts. And then the last piece you'll see in the first half of '27 is the approval of NXT-41x.

Then lastly, before I turn the call over to Matt, just a little bit about what's going on inside the company and when we -- when we talk next about this, what I'll be providing updates, there are already three really essential work streams going on. Obviously, the most important one is the development. And we're looking for the development and approval of a highly differentiated product that significantly improves outcomes in plastic and reconstructive surgery, that is NXT-41. But alongside all of that is our manufacturing team that are building out this robust production platform that's able to achieve really, really significantly low cost of goods through our own proprietary in-house manufacturing process. We have this manufacturing facility in Gaithersburg, Maryland. If you're ever in the area, stop by, we'd love to give you a tour about it. But we have this really great facility and this really great team there that's building out this process that will enable us to produce this at a low cost of goods. And then lastly, the commercial team. The commercial team is working on SimpliDerm and doing a great job with SimpliDerm, but also building out the clinical advocacy and the commercial infrastructure that we need to have in place so that when 41x gets approved, we're able to do as good a job, if not a better job commercializing that product as we were able to do with EluPro. So that is what we're doing. That is why we're doing it and our plan in order to get from here to there.

With that, I'll turn the call over to Matt, and he'll tell you about our operations.

Okay. Thanks, Randy. And it's a very exciting time to be at Elutia and the future that Randy just described for everyone is really built on the great work that has been done over the past several years and the work that's been done more recently to build the foundation to make this future possible that we are also excited about. And so with that, I'm going to just take us back briefly to what Randy talked about at the very beginning of the call. And the big event for the third quarter of 2025, was the transaction of the sale of the bioennvelope business within Elutia to Boston Scientific. It was a sale for $88 million in cash, sold to a Tier 1 company that really put us through our paces digging under the covers, not just for the assets that they were acquiring, but really the whole company. And we came through that process very nicely with the technology and the company validated for work that had been going on really for years. So that transaction validates the technology platform that will be transformed in the coming quarters into NXT-41 and 41x and capture this big opportunity. And it also transforms our balance sheet importantly. And so it brings in a significant amount of cash and then it also streamlines our operations.

So going forward, we'll be more nimble and we'll be more efficient and will be more productive. So the assets that were sold were the EluPro and CanGaroo products, along with that, our main operational facility within Roswell, Georgia that also went with the transaction. About half of the people in the company also went with that transaction. So that is going to make a big difference in our operating expense going forward and also should lead to improved bottom lines for the company. The transaction was announced in early September, but it didn't close until Q4, but it actually closed on the first day of Q4. So while the financial results, the balance sheet that we show as of the end of the quarter doesn't yet reflect the infusion of cash and the other associated payoff of debt and that sort of thing that occurred with the transaction, that happened just the day after the end of the quarter, and we'll talk a little bit more about that in a second.

So from a financial point of view, when you look at our financials going forward, the business of the Bioennvelope division, that will now be shown just as a single line in discontinued operations. So starting with Q3 this quarter, we are no longer reporting on the sales and expenses associated with that part of the business, except in that one line, which is below our operating line at this point. So just moving forward, talking a little bit about the results for the quarter of the continuing operations, really breaks down into our 2 other product lines that are commercial right now, that's SimpliDerm and cardiovascular. SimpliDerm, we saw a nice uptick from the prior quarter in revenue. We generated $2.4 million of revenue, which was up about 18% from Q2 of this year. It was down, granted from a year ago, but there are a variety of factors that caused that over time. A lot of it, we believe, had to do with the contributions from the distribution partner that we've had over time. And I can say that we've actually now ended that relationship as of October, and we now have full control over that product line, and it is unencumbered from a strategic point of view. But just as important, we now have full operational control over it.

As we rebuild the commercial footprint associated with that part of the business, it will do a couple of things. One, it will lead to renewed growth of that part of the business, but we'll also very importantly, lay the groundwork, which Randy talked about a little bit for the products, NXT-41, NXT-41x, which are sold into the same customer base and into the same types of procedures that SimpliDerm is sold into. So you can think of it a little bit similar to what we did with EluPro, where we had the CanGaroo product before we had the EluPro drug-eluting version of the product. Having that sales organization and commercial footprint for CanGaroo really allowed us to hit the ground running. And by the time that we were 3 quarters into our launch, we had ramped up to about an $18 million run rate with EluPro, and we think we can likely do even better when we have NXT-41 on the market.

Moving on to cardiovascular. That also had a nice quarter, again, with the theme of us regaining control over the product completely. We returned to full operational control of that product after having a distribution partner there as well in the second quarter. And in May, we started selling that directly ourselves, and we generated in the third quarter, the first full quarter where we had only direct sales, we generated just a little under $1.9 million of sales with that. And that actually compares to both the prior year and the prior quarter quite nicely. It was up 68% from the prior year, up 28% sequentially. So we're doing nicely there. That product also has very high gross margin. So the more we sell there, the more it drops to our bottom line and funds the really strategic opportunities that we have in front of us.

Moving on to a few other financial highlights in our statement of operations. Overall sales were $3.3 million, comprised of those 2 product lines that I just talked through compared to $3.6 million from a year ago quarter. The GAAP gross margin was 55.8% versus about 49% a year ago. So we've seen a nice uptick in our gross margin. There, again, we're actually benefiting from the margin profile of these products that we're now selling compared to the full portfolio that we had previously. And I think we'll see continued gains there.

Our adjusted gross margin, which excludes noncash amortization expense, that was even better at about 64% versus 56% in the year ago quarter. And then also, we saw improvements both from an operating expense point of view and a loss from operations perspective. So we were at $7.1 million in overall operating expense, down from $11 million a year ago, and our loss from operations was $5.2 million versus about $9 million a year ago. All of that nets out to what was probably a more important metric when you back out the noncash items and nonrecurring items, our adjusted EBITDA was $2.7 -- adjusted EBITDA loss for the quarter was $2.7 million, and I think that's a pretty good indication of where we expect to be in the near future.

From a balance sheet perspective, again, as I mentioned, the transaction had not closed yet by the end of the quarter. So we ended the quarter with $4.7 million in cash. But again, 1 day later, we closed the transaction that resulted in $80 million coming in at closing, $8 million in escrow and interest-bearing escrow account that we'll receive in 2026. That $80 million was then deployed to pay off about $28 million of debt. And then after paying off deal expenses and the like, we ended up with about $49 million of actual cash that came into our account in early October. That puts us in a great position as we move forward and think about our development plans going ahead. So we believe that gives us the runway to get us completely through the development and approval of NXT-41 and NXT-41x and the actual commercial launch of those products out in 2026 and 2027.

Then finally, for people who've been watching the company for some time, you know that we have been working very diligently to put behind us some legacy litigation from a part of the company that we sold off a couple of years ago. That's generally referred to as the FiberCel litigation. I can report there that we were able to resolve another 7 of those cases in the quarter. And now when we started with 110 of those cases, we're now down to only 6 remaining. So I can say we are very, very close to putting that completely in the rearview mirror for us. We're very glad to have that almost behind us. And from a financial point of view, it's a relatively small number that those remaining 6 cases account for. The estimated liability of those is less than $1 million at about $700,000.

So with those highlights, just before we take your questions, I would say, if you think about it from a big picture, why as an investor, would you own Elutia? Well, it goes back to the opportunity really that we've been talking about here for the last half hour or so. We like to say that it's a biotech-like upside with the risk profile and time line of med tech. So it's something that is very unique in the marketplace. We have a validated technology platform that physicians will adopt and that strategic will value. We have a derisked path to be first-in-class in a $1.5 billion market with a significant unmet medical need. And we have the team and the capital to get there without dilution.

So with that, we'll take your questions.

[Operator Instructions] It's from Frank Takkinen with Lake Street Capital Markets.

This is Nelson Cox on the line for Frank. Congrats on all the progress. It's exciting to see the story developing. You walked through it during the prepared remarks, but maybe just to go a little deeper, maybe walk through some of the learnings with EluPro from a development to approval to commercial rollout perspective. Just want to give you a chance to maybe dive into that a bit more and any learnings that will translate to NXT.

Yes. Thanks, Nelson. So first, I would say the team is everything. And that goes to development, FDA approval and commercial rollout as well. The team is really everything here. And so with EluPro, we actually had a submission of EluPro that was put in actually before my time coming back into the company. And we got some comments back from the -- we got a lot of comments back from the FDA about that. And that led actually to us getting an NSC on that. But through that nonsubstantial equivalence process, I brought in Michelle Williams, who you guys know I've worked with for 21 years now. And I would say best Chief Scientific Officer in the business for these kinds of things. And she was able to really not just respond to the NSC, but also learn from it and develop our own intellectual property around it on not just delivery methods for local antibiotic delivery, but also around testing methods and how you prove it and how you demonstrate it to the FDA. And in doing so, develop a really good relationship with the agency, giving them not just barely enough information to feel comfortable with the submission and the clearance, but actually making them feel really confident that we've made a real quality product here.

So I would say that is probably the single most important thing from a development standpoint that we learned. Commercially, what we learned was it is really good to have some commercial infrastructure in place. EluPro, by the time we sold EluPro to Boston Scientific, it was running at an $18 million run rate; 9 months in, I mean, that thing shot out of a canon. And that was because we had a commercial team in place. They had a great VAC package that, again, Michelle Williams and her team had helped put together. But we also had the commercial infrastructure and the contracting in place, and we knew how to do that. And so CanGaroo helped EluPro, and we think in the same way, SimpliDerm is going to help 41x when we get out there. So I think those are 2 things that come to mind.

Then maybe just running off of that, SimpliDerm obviously gives you a big commercial presence like you're talking about ahead of NXT. Can you just frame that a bit more for us and how you plan to leverage those already existing relationships.

Yes. So we're talking about -- when we have SimpliDerm, right, we're talking about biological mesh that's used in the same surgical procedures. It's used by exactly the same surgeons in pretty much exactly the same way we expect NXT-41x to get used, right? So we're not talking about requiring the surgeons to do anything different from their current practice. It's one of the reasons that we just -- we really love -- we love this approach. All of it's already in place. They're already doing it. The problem they have is despite their best efforts, they're left with this postoperative complication rate. And so our plans with SimpliDerm is to just keep using that product to have this direct customer interaction that we have. Nobody between us. As Matt said, we now have full control back of our SimpliDerm product line. We go out and meet directly with the plastic and reconstructive surgeons. We talk with them about how SimpliDerm is going and their problems and how we can be helpful and how we can have them get better outcomes. And then obviously, just from a commercial infrastructure standpoint, our contracting teams and our commercial teams from a customer service and distribution, all that stuff is in place and ready to go, and we'll keep building on it, right?

So we think about this coming year, not in any way as an idle year for our commercial team, but it's actually one where they're going to be active as hell going out there and continuing to expand this in just the same ways that we did with CanGaroo before the launch of EluPro. Every seed we planted there ended up being very, very valuable for the launch of that product. And we learned that lesson. And so that's what we're going to do with SimpliDerm.

Maybe just sneak one more in. How are you thinking about kind of clinical evidence and data generation with NXT? Do you envision kind of needing to invest there significantly to drive education and adoption?

So through the combination 510(k) pathway, as you know, we actually don't have a requirement for clinical data for the approval process. Now we are a science-based company. We do really exceptional quality work, and we stand behind it. When we launched EluPro, we had no requirement for clinical data. But very quickly, we were able to put together, as part of our VAC package and as part of our marketing package, a complete story that made the implanting surgeons not just comfortable but enthusiastic about putting EluPro, and that worked really, really well. Well, we're doing the same thing here. And so preclinically, there is a tremendous amount of evidence that the team is building from things like pharmacokinetics, how long the antibiotics are there, the concentrations that they hang around in surgical sites from a preclinical efficacy standpoint. One of the things you can't do with patients is you can't go back into them a month after the product has been implanted and infuse them or inject them with large amounts of pathogenic bacteria. But we can do that in the preclinical setting with animal models and demonstrate like we did with EluPro that we're able to get complete kill even at 4 weeks out. But once the product, Nelson, comes to market, one, we don't think -- we know there's strong demand for this product now from the interactions that we have from the relationships that we have now, just the same way EluPro.

There is a first wave of users that are ready to be done with putting cement into breasts in order to fix this problem and have a professionally built and constructed a product that fits in with their practice and they'll adopt right away. But we're not leaving it there. We're running clinical programs on these so that we generate conclusive data. Our goal here isn't to take significant market share. Our goal here is to flip the entire market so that women have much, much better outcomes than they currently do. The current standard of practice is not okay to leave the way it is. It needs to get better. And we know we'll have to generate clinical data to get all of that done, but that is our goal, all of it.

Our next question is from the line of Ross Osborn with Cantor Fitzgerald.

This is Matt Park on for Ross today. So I guess starting off with 41 and 41x. Can you just go back to any manufacturing plans you need to do ahead of time to -- I guess, like are there any validation steps needed to ensure a smooth transition from SimpliDerm to 41 and then to 41x?

Great question, Matt. So to be really clear, where we manufacture 41, 41x is a completely different facility than we manufacture SimpliDerm. SimpliDerm is a human-derived product. It has a host of regulations associated with it because human-derived products can carry human pathogens with them. And so we keep those 2 things completely separate in completely separate facilities. So the facility where we're manufacturing 41 and 41x is a GMP facility. We were really, really lucky here. You might say we were beneficiaries of the GLP-1 boon that occurred in that we were able to get a space, a great GMP space that was already built out and ready to go from a company that was acquired by Novo Nordisk. And because of that, we were able to get it at really great prices. But most importantly, it was this really high-quality facility that was ready to go looking for somebody to manufacture something in it.

So we're really pleased with that facility. There's all kinds of tech transfer and process qualification, equipment qualification that goes on when you bring up a manufacturing process. We have all of -- our teams there have a schedule for all of 2026. They're running through that process right now and are underway. We don't anticipate manufacturing will hold back or be the rate limiting factor in anything that we're doing here. And by the way, facility-wise, this is all done out of our new facility in Gaithersburg, Maryland.

Maybe just one more on the cardiovascular business. Now that you've transitioned it back in-house, I guess, how should we think about the current run rate and the sustainability of growth from here?

Yes, Matt. So we've been really pleased with the bounce back that we've seen now that we've been able to devote some more attention and some direct resources to that part of the business. That is not the future of the company by any means, but it's a great little business that has a pretty significant market out there and great gross margins and some really committed physicians out there that are using the products. And so we're basically back at the $1 million a quarter revenue level. And I think there's some growth that we can achieve from there. But it's not going to be a rocket ship. It's going to be steady growth, but we're also not having to invest money upfront in order to achieve that. We've got really an exclusively contract sales organization that's out there. So it's completely variable expense. And with the high gross margins over 80% that we've been achieving there, it -- a significant amount of the revenue that we generate actually drops to the bottom line. So that's in general, how I would think about the product there -- the product and the future trajectory there.

Got it. Thanks again for taking the questions and congrats on progress.

As I see no further questions in the queue, I will conclude the Q&A session and conference for today. Thank you all for participating. You may now disconnect.